



Cite this: DOI: 10.1039/d4tb00741g

Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy

Shurong Qin,^{†a} Guanzhong He^{†a} and Jingjing Yang ^{*b}

Cancer remains the leading cause of human death worldwide. Compared to traditional therapies, tumor immunotherapy has received a lot of attention and research focus due to its potential to activate both innate and adaptive immunity, low toxicity to normal tissue, and long-term immune activity. However, its clinical effectiveness and large-scale application are limited due to the immunosuppression microenvironment, lack of spatiotemporal control, expensive cost, and long manufacturing time. Recently, nanomaterial combined engineered bacteria have emerged as a promising solution to the challenges of tumor immunotherapy, which offers spatiotemporal control, reversal of immunosuppression, and scalable production. Therefore, we summarize the latest research on nanomaterial-assisted engineered bacteria for precise tumor immunotherapies, including the cross-talk of nanomaterials and bacteria as well as their application in different immunotherapies. In addition, we further discuss the advantages and challenges of nanomaterial-engineered bacteria and their future prospects, inspiring more novel and intelligent tumor immunotherapy.

Received 5th April 2024,
Accepted 9th August 2024

DOI: 10.1039/d4tb00741g

rsc.li/materials-b

1. Introduction

In 2020, the World Health Organization reported that cancer was the leading cause of human fatality under the age of 70 in 112 countries.¹ The most common methods for treating tumors are surgery, chemotherapy, and radiotherapy (RT), but their

effectiveness is not satisfactory due to limited tumor targeting, insufficient tumor penetration, unfavorable prognosis, and a high probability of recurrence and metastasis.² Surgical resection of tumors is a simple and direct method of treating tumors, but due to the low rate of local surgical resection and incomplete tumor resection, it is easy to cause tumor recurrence and metastasis.³ Chemotherapeutic drugs are susceptible to abnormal accumulation in normal tissues such as the liver, kidneys, and lungs due to poor targeting and selectivity, resulting in toxicity to healthy tissues and the immune system.⁴ Moreover, the poor tumor penetration and early multi-drug resistance of chemotherapy drugs further limit their clinical effectiveness.⁵ Similarly, although 77% of lung cancer patients have indications for RT, radiation toxicity due to accidental irradiation of adjacent tissues still exists, which would limit the application of RT in cancer treatment.⁶ Tumor immunotherapy is now considered a milestone in cancer treatment, due to its safety in normal tissues, potential to activate innate and specific immunity, and long-term immune memory.⁷ However, many difficulties and challenges still limit the effectiveness of immunotherapy in clinical treatment. For example, PD-L1 inhibitors are ineffective in most patients (more than 70%) due to the tumor immunosuppression microenvironment and immune escape mechanisms.⁸ Although chimeric antigen receptor T cell (CAR-T) therapy has achieved breakthrough success in treating hematological malignancies, its efficacy in solid tumors remains limited and requires further improvement.⁹ Therefore, further understanding of tumor immunology and novel approaches such as engineered bacterial oncotherapy are needed to improve cancer immunotherapy.

^a College of Engineering and Applied Sciences, State Key Laboratory of Analytical Chemistry for Life Science, Jiangsu Key Laboratory of Artificial Functional Materials, Nanjing University, Nanjing 210023, China

^b Department of Biochemistry and Molecular Biology, School of Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization Nanjing University of Chinese Medicine, Nanjing 210023, China.
E-mail: jingjingyang@njucm.edu.cn

[†] These authors contribute equally.



Jingjing Yang

Jingjing Yang is currently an associate professor at the School of Medicine, Nanjing University of Chinese Medicine. She received her PhD degree from the College of Engineering and Applied Sciences, Nanjing University, in 2021. In the same year, she joined Nanjing University of Chinese Medicine. Her current research focuses on biofunctional materials and microfluidics for tumor diagnosis and treatment.

The use of bacteria as an anti-tumor therapy has a long history.¹⁰ As early as 1863, W. Busch and his colleagues first discovered that infection with *Streptococcus pyogenes* could cause a patient's tumor mass regression. However, due to the inability to control the further infection of bacteria, the patient ultimately died.¹¹ In 1898, William Coley and his colleagues further explored the reasons behind the bacteria's ability to shrink tumors, as well as the cause of the patient's death. Coley administered a mixture of heat-inactivated *Serratia marcescens* and *Streptococcus pyogenes* bacteria (now known as "Coley's toxin") to many patients with unresectable soft tissue sarcomas.^{12,13} This treatment was surprisingly effective, but it caused a strong fever reaction, with patients' temperatures reaching 38–40 °C.¹⁴ After this discovery, the use of microorganisms, such as *Clostridium*, *Listeria*, *Escherichia*, and other bacteria, as a new tumor immunotherapy ignited the enthusiasm of researchers in the early 20th century.¹⁵ However, this first-generation bacterial therapy, mainly relying on natural or inactivated bacteria, did not continue to be researched due to its tendency to cause toxic shock and infection risks.¹⁶ With the development of molecular biology technology, second-generation bacterial therapy can use DNA recombinant technology to enable precise modification of bacterial DNA, thereby achieving precise regulation of bacterial behavior and function.¹⁷ Some genetically engineered bacteria can achieve reduced systemic toxicity by selectively knocking out virulence factor genes, such as *Salmonella* VNP20009.¹⁸ The others can be genetically programmed to express genes encoding antibodies or cytokines to regulate the tumor microenvironment (TME), such as programmed cell death 1 ligand 1 (PD-L1),¹⁹ cytotoxic T lymphocyte associate protein-4 (CTLA-4),²⁰ and tumor necrosis factor- α (TNF- α)²¹ nanobodies. There are also some engineered bacteria that can kill tumor cells by disrupting tumor metabolism and producing their own metabolites. For example, engineered bacteria producing 5-ALA can convert it into protoporphyrin in tumor cells, which can then be ablated by near-infrared light irradiation.²² However due to the serious biosafety concerns and lack of spatiotemporal control, second-generation bacterial therapy is still not an ideal and intelligent therapy.

The third generation bacterial tumor therapy uses nanoparticle-assisted engineered bacteria, and has solved the dilemma of previous bacterial therapy and provided a new avenue for intelligent tumor immunotherapy.²³ Recently, the development of nanotechnology has advanced bacterial therapy to a higher level by integrating multifunctional nanomaterials on or inside the bacteria. Yu and his colleagues encapsulated hematoporphyrin monomethyl ether (HMME) in ZIF-8, and then constructed MHS nanoparticles by adsorbing Cas9/sgRNA. These nanoparticles were subsequently combined on the surface of *Lactobacillus plantarum*, which in response to the acidic TME releases the CRISPR/Cas9 system and induces the enhancement of immunogenic cell death (ICD) and the maturation of dendritic cells (DCs), finally reversing the tumor immune microenvironment to ablate the tumor.²⁴ Polydopamine-coated *Escherichia coli* Nissle 1917 (EcN) bearing

CRISPR-Cas9 plasmid-loaded liposomes (Lipo-P), which could improve therapeutic agent penetration in tumor centers and reduce the thermal resistance of cancer cells, is utilized to enhance immunotherapy in deep tumors by activating both innate and adaptive immunity.²⁵ A metal-based photosensitizer-bacteria hybrid Ir-HEcN, obtained by covalently labeling an iridium(III) photosensitizer to the surface of genetically engineered bacteria, was capable of inducing pyroptosis and ICD in tumor cells under a 525 nm laser.²⁶ Interesting, bioluminescent bacteria transformed with the Luc-S.T. Δ ppGpp plasmid serve as an internal light source, enabling effective photodynamic therapy (PDT) due to continuous light generation to excite photosensitizer chlorine6, enhancing antitumor immunity and effective suppression in opaque melanoma and large rabbit tumors.²⁷ In summary, the nanoparticle-assisted engineered bacteria play a crucial role in cancer immunotherapy by enabling spatiotemporal control, enhancing tumor targeting, expanding the functionality of bacteria, and enabling real-time detection.


Hence in this review, we have focused on the cross-talk between nanomaterials and engineered bacteria, then summarized the latest research on nanoparticle-assisted engineered bacteria in different types of cancer immunotherapy, including immune checkpoint therapy, tumor vaccination, CAR-T, and nonspecific immunity (Scheme 1). Moreover, we have discussed the advantages and limitations of the current nanoparticle combined engineered bacteria hybrid system. In the end, we have proposed a possible future perspective on the third bacterial therapy, hoping to inspire novel ideas and methods to modify the engineered bacteria to enhance the efficacy of immunotherapy.

2. The cross-talk roles of nanomaterials and bacteria

2.1 The effect of nanomaterials on bacteria

Engineering bacteria have achieved significant progress, but clinical translation remains unsatisfactory, primarily due to the challenge of effectively controlling bacterial behavior and function within a biological organism. Nanomaterial modification on bacterial surfaces or within bacteria *via* different reactions could allow bacteria to respond to external signals, such as light, magnetic, electric, acoustic, and radiation signals for imaging, activation of promoters, and precise spatiotemporal control of drug release (Table 1).

2.1.1 Response to light. Among these external stimuli, light has been widely exploited for nanomaterial-bacteria hybrid systems due to its non-invasive nature, spatiotemporal precision, and ease of manipulation.⁵⁰ In particular, photothermal therapy (PTT) based on light-responsive nanomaterial-engineered bacteria has emerged as a promising approach for targeted tumor ablation. The efficacy of PTT primarily hinges on a photothermal transduction agent (PTA) that converts NIR energy into thermal energy, thereby inducing hyperthermia in malignant cells.⁵¹ However, while nanocarriers have been



Scheme 1 Nanoparticle combined engineered bacteria applied in cancer immunotherapy. Created with BioRender.com.

engineered to mitigate some physiological barriers due to the enhanced permeability and retention (EPR) effect, traditional nanocarriers still face challenges in effectively targeting hypoxic tumor tissues due to their limited tumor-targeting capacity. To address this challenge, Chen *et al.* have developed a novel biotic/abiotic hybrid system that involves the binding of indocyanine green (ICG)-loaded nanoparticles (INPs) to *Salmonella typhimurium* YB1 (YB1) for precise tumor therapy. This strategic approach enables for the effective penetration of INPs into hypoxic tumor tissues facilitated by YB1's tumor-homing ability. Upon NIR irradiation, the photothermal effects of INPs lead to the lysis of tumor cells, loosening the tumor tissues and releasing nutrients from the destroyed cells. This process, in turn, promotes the further penetration of YB1 in the TME, and results in a 14-fold increase in INP accumulation at tumor sites compared to conditions without NIR irradiation.²⁸ Utilizing the unique attributes of bacteria as above, employing specific strains to fabricate photothermal agents on their surfaces emerges as a promising strategy for PTT.

However, the inherent heat resistance of tumor cells and energy dissipation in deep tumor tissues may lead to the adaptation of certain resilient tumor cells to high-temperature thermal treatments.⁵² To overcome this limitation, Chen *et al.* developed a self-mineralized photothermal bacterium (PTB)

using *Shewanella oneidensis* MR-1 to biomineralize palladium nanoparticles on its surfaces, and it was found to exhibit superior photothermal properties under NIR irradiation. They further constructed a hybrid bacterial system by conjugating ZIF-90-encapsulating MB to the bacterial surface (PTB@ZIF-90/MB). Under NIR irradiation, MB generated reactive oxygen species (ROS) to inhibit adenosine triphosphate (ATP) production and downregulate heat shock proteins by interfering with mitochondrial redox equilibrium. This hybrid system combined the precise tumor-targeting ability of the self-mineralized bacteria with the mitochondrial dysfunction-inducing capability of MB, providing a new approach for enhanced PTT.²⁹ By overcoming tumor heat endurance and achieving precise tumor targeting, this strategy could potentially improve the efficacy of PTT. Similarly, Luo *et al.* employed the polydopamine-coated EcN bearing CRISPR-Cas9 plasmid-loaded liposomes (Fig. 1A), which could improve therapeutic agent penetration in tumor centers and reduce the thermal resistance of cancer cells, thus enhancing the PTT effect and immunotherapy in deep tumors.⁵³ Moreover, Wang *et al.* developed a photothermal hybrid bacterial system (EM@Au) by using *E. coli* MG1655 to self-mineralize gold nanoparticles (Au NPs) on the bacterial surface. The *E. coli* was transformed with plasmids containing thermally sensitive promoters and the

Table 1 Summary of research on nanomaterials promoting engineered bacteria responsive to external signals

| External signal | Nanomaterial | Bacteria | Tumor type | Cargo | Anti-tumor mechanism | Ref. |
|-----------------|---|-------------------------------------|-----------------|------------------------|--|----------|
| Light | INP | <i>Salmonella typhimurium</i> (YB1) | MB49 | ICG | PPT/PDT | 28 |
| | ZIF-90 | <i>Shewanella oneidensis</i> | CT26 | Prussian blue | PPT and downregulate HSP90 | 29 |
| | PDA-liposome | EcN | 4T1 | HSP90 plasmid | HSP90 knockdown and enhanced PPT | 25 |
| | Au NPs | <i>E. coli</i> MG1655 | CT26 | ClyA plasmid | PPT and ClyA expression | 30 |
| | Polydopamine | EcN | CT26-OVA | OVA and α -PD-1 | Enhanced ICD and activation of T cells | 31 |
| | Au nanodot | EcN | MC38-OVA 4T1 | 5-FU and ZOL | PPT, chemotherapy and polarization of macrophages | 32 |
| | HAS/ICG UCNP | <i>Synchronous</i> 7942 EcN | 4T1 H22 and 4T1 | ICG FlaB plasmid | Oxygen generation and enhanced PDT Activation of TLR5 and polarization of macrophages | 33 34 |
| Magnetic field | Fe ₃ O ₄ @lipid nanocomposite | <i>E. coli</i> BL21 | CT26 and 4T1 | CD47 Nb | Release of CD47 Nb and reactivation of macrophages | 35 |
| | Magnetic nanoparticle | EcN | CT26 | NDH-2 | Magnetothermal ablation and NDH-2-induced ROS | 36 |
| | Fe ₃ O ₄ NPs | <i>S. platensis</i> | 4T1 | Chlorophyll | Chlorophyll-induced ROS enhanced RT | 37 |
| | INP | <i>Magneto spirillum magnetism</i> | MCF-7 | ICG | PTT/PDT | 38 |
| Ultrasound | — | <i>E. coli</i> MG1655 | 4T1 and H22-Luc | IFN- γ | Apoptosis of cancer cells and polarization of macrophages | 39 |
| | DOX-PFP-PLGA nanodroplets | <i>E. coli</i> MG1655 | 4T1 | — | Ultrasound-trigger drug release and enhanced chemotherapy | 40 |
| | Gas vesicle | <i>E. coli</i> BL21 | 4T1 | Gas vesicle | Mechanical damage of cancer cells | 41 |
| | IPA-CLs | <i>E. coli</i> BL21 | 4T1 | Gas vesicle | Hypoxia-activated chemotherapy | 42 |
| Radiation | Bi ₂ S ₃ NPs | <i>E. coli</i> MG1655 | 4T1-Luc | ClyA plasmid | Arrest cancer cell cycle and enhanced RT | 43 |
| | GTe | Fusion membrane | 4T1 | GTe | Sensitizing RT and enhanced ICD | 44 |
| | — | EcN | 4T1 | Catalase | Oxygen sensitive RT with improved ROS generation | 45 |
| | Nanovesicles | Bacterial membrane | CT26 | Catalase | Long-term tumor hypoxia relief and enhanced RT | 46 |
| Electricity | γ -Fe ₂ O ₃ | <i>S. putrefaciens</i> CN32 | — | — | Improved extracellular electron transfer and bioelectricity generation | 47 |
| | Carbon dots | <i>S. oneidensis</i> MR-1 | — | — | Boosted bacterial metabolism, electron transfer, and bioelectricity generation | 48 |
| | Polydopamine | <i>Synechocystis</i> sp. PCC6803 | — | — | Enhanced charge transfer | 49 |

gene for ClyA, enabling precise control over the expression of therapeutic proteins. Upon NIR irradiation, the heat generated by Au NPs triggered the expression of ClyA, resulting in the targeted killing of tumor cells.³⁰

Many studies have demonstrated that the complete elimination of residual tumor cells post-PTT primarily hinges on the stimulation of antitumor immune responses. However, elevated local inflammatory reactions, exacerbated by inflammatory factors and immune cells like tumor-associated macrophages (TAMs) recruited due to high temperatures, accelerate the development of an immunosuppressive microenvironment and immune evasion processes.⁵⁴ Therefore, combining PTT with other modalities to activate immune systems and remodel the post-PTT microenvironment offers a viable strategy to enhance therapeutic outcomes. Bacteria with superior tumor site tracing and colonization capabilities are valuable for efficient multidrug loading and precise release regulation, further

improving PPT treatment efficacy. Li *et al.* have developed a method to enhance tumor-specific immunotherapy using bacteria decorated with tumor-specific antigens and checkpoint blocking antibodies *via* polydopamine nanoparticles, which not only serve as a linker but also have a photothermal agent. When administered to tumor-bearing animals, the decorated bacteria show long tumor retention and demonstrate potent antitumor effects in tumor models. This approach presents a versatile platform for delivering tumor antigens, activating DCs, and reversing the immunosuppressive microenvironment through immune checkpoint inhibitors in a synergistic PPT-immunotherapy.³¹ Xie *et al.* developed a bacterial navigation hybrid system EcN_{Z/F}@Au by incorporating 5-fluorouracil (5-Fu) and zoledronic acid (ZOL) into EcN, followed by Au nanodot modification on the EcN surface. EcN_{Z/F}@Au autonomously navigated to tumor sites, and *in situ* transformed into biofilm-like granules (BGs) under the photothermal effect of Au nanodots




Fig. 1 The nanomaterial-assisted engineered bacteria responded to external signals due to extracellular or intracellular nanoparticles. (A) A polydopamine-coated *E. coli* hybrid system bearing CRISPR-Cas9 plasmid-loaded liposomes (Lipo-P) responded to NIR.⁵³ Reproduced from ref. 53 with permission from ACS Publication, copyright 2023. (B) An engineered *Escherichia coli* with Fe_3O_4 @lipid nanocomposites responded to the magnetic field.³⁵ Reproduced from ref. 35 with permission from Springer, copyright 2023. (C) *E. coli* BL21 was genetically engineered by introducing a gene cluster encoding GVs and it responded to acoustic tweezers.⁴¹ Reproduced from ref. 41 with permission from Springer, copyright 2023. (D) An integrated nanosystem (Bac@BNP) composed of engineered bacteria (Bac) and Bi_2S_3 nanoparticles (BNPs) responded to radiation.⁴³ Reproduced from ref. 43 with permission from ACS Publication, copyright 2022.

triggered by NIR irradiation. In addition to the chemotherapeutic effect of FU, ZOL released from BGs promoted the polarization of TAMs from the M2 phenotype towards the antitumor M1 phenotype. And then these M1 TAMs secreted proinflammatory cytokines, reversing the immunosuppressive microenvironment and enhancing the synergistic efficacy of PTT, chemotherapy, and immunotherapy.³²

PDT is a promising emerging technique due to its minimal invasiveness, low systemic toxicity, and limited drug resistance, making it a viable option for cancer treatment. It relies on the generation of ROS from photosensitizers (PSS) under laser exposure, which subsequently induces oxidative damage, apoptosis, and necrosis in tumor cells.⁵⁵ However, the severe hypoxia in the TME poses a significant challenge in ROS generation, limiting the therapeutic effectiveness of PDT. Thus, numerous studies have attempted to alleviate tumor hypoxia to achieve efficient ROS generation in PDT. These approaches

include using oxygen-evolving nanomaterials (*e.g.*, MnO_2 NPs),⁵⁶ oxygen-carrying vectors (*e.g.*, perfluorocarbon),⁵⁷ and biocatalyzers (*e.g.*, CAT).⁵⁸ Moreover, Liu *et al.* developed an engineered *Synchronous* for tumor-targeted delivery of ICG and *in situ* oxygen generation to facilitate photosynthesis-assisted PDT. In this system, ICG and human serum albumin (HSA) were first assembled into HSA/ICG NPs *via* disulfide bonds. Then, these NPs were coupled onto the *Syne* cell wall *via* amide bonds, creating the biomimetic system S/HAS/ICG. This system could effectively target tumor sites and increase local O_2 levels through photosynthetic reactions, significantly enhancing the therapeutic efficacy of PDT and immune stimulation under 660 nm laser irradiation.³³

In addition, optogenetics has emerged as a novel method to control molecular and cellular behaviors by combining optical and genetic technologies.⁵⁹ Zhang *et al.* constructed a light-controlled engineered bacteria system using upconversion

nanoparticles (UCNPs) for accurate tumor diagnosis and therapy in colorectal cancer. The system achieves co-localization of engineered bacteria and UCNPs in tumor tissues, improving diagnostic accuracy, and triggers tumor cell death by releasing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) upon blue light irradiation. *In vitro* and *in vivo* experiments demonstrate the effectiveness of the system in accurate tumor diagnosis and light-controlled cancer therapy.⁶⁰ Moreover, Wu *et al.* developed a two-step therapy platform for treating primary and distant tumors using UCNPs and engineered bacteria. Firstly, erbium ion (Er³⁺)-doped UCNPs activate the photosensitizer ZnPc to target primary tumors by generating ¹O₂. Secondly, thulium ion (Tm³⁺)-doped UCNPs emit blue-violet light upon NIR excitation, triggering engineered bacteria to produce interferon (INF- γ) in the intestine. This dual approach not only directly treats tumors but also enhances the immune response, synergistically inhibiting the growth of distant tumors through joint immunotherapy.⁶¹

2.1.2 Response to the magnetic field. NIR-inducible heat promoters (pL/pR)⁶² and blue light-inducible promoters (pDawn)⁶³ can also realize spatiotemporal control, but the tissue penetration of near-infrared or blue light is shorter than several millimeters with limited clinical application. Therefore, the magnetic field, a noninvasive energy form that targets specific anatomical sites like solid tumors, proves to be an effective tool for manipulating bacterial gene expression *in vivo*, activating therapeutic microbes and significantly suppressing tumor growth. Zoher Gueroui *et al.* have used synthetic biology to engineer *E. coli* into MagEcoli, which can be manipulated spatially when exposed to magnetic fields to achieve targeted cell capture and regulate invasion of human cells.⁵⁹ In addition, Nie *et al.* developed alternating magnetic field (AMF)-manipulated tumor-homing bacteria (AMF-Bac) by genetically modifying an *E. coli* BL21 attenuated strain with a Fe₃O₄@lipid nanocomposite. The AMF-Bac, equipped with five functional modules similar to machinery robots, actively navigates to orthotopic colon tumors, decodes magnetic signals, processes and releases immunotherapeutic drugs, such as the anti-CD47 nanobody, specifically targeting tumors and avoiding hematologic toxicity (Fig. 1B).³⁵ Similarly, the EcN@MNPs hybrid system possesses the capacity for magnetic actuation to direct themselves to tumor sites. The magnetic nanoparticles (MNPs) act as a magnetothermal switch, collaborating with a thermally sensitive promoter to activate the expression of mCherry and NDH-2, thereby improving the therapeutic effectiveness against tumors.³⁶ Furthermore, Zhong *et al.* utilized Fe₃O₄ NP modified *S. platensis* to construct magnetic biohybrid nanoswimmers. These nanoswimmers could be guided to tumor sites by an external magnetic field, where they generated oxygen through photosynthesis to alleviate tumor hypoxia, and facilitated a synergistic antitumor effect through chlorophyll-induced ROS generation under laser irradiation. This work combined *S. platensis* with Fe₃O₄ NPs for precise diagnosis and synergistic therapy, integrating RT and PDT.³⁷ Xing and colleagues have introduced a novel biomicrobot, actuated by magnetism and triggered optically, consisting of *Magneto*

spirillum magnetism (AMB-1) and ICG NPs. This biomicrobot has successfully achieved both fluorescence and MRI bimodal imaging, allowing for real-time detection of its *in vivo* distribution.³⁸

2.1.3 Response to ultrasound. Focused ultrasound, with excellent tissue penetration and localization capabilities, can transmit energy through superficial tissues and can be focused on target tissues at specific depths, eliciting biological effects that expedite the rapid recovery of pathological tissues.⁶⁴ Additionally, the dosage of focused ultrasound therapy is easily controllable, ensuring high safety. Following treatment, only transient congestion and edema are observed in treated areas, while superficial cells remain intact, leading to fast postoperative recovery.⁶⁴ These advantages make focused ultrasound an excellent non-invasive, remotely regulated tool for the treatment of various diseases, particularly in the field of oncology. In recent years, researchers have explored the potential of combining focused ultrasound with engineered bacteria for targeted cancer therapy. For instance, Abedi *et al.* developed an ultrasound-thermal responsive promoter Tc142 and a GFP reporter gene construct in EcN, which could express and release the immune checkpoints CTLA-4 and PD-L1 nanobody to suppress tumor growth.⁶⁵ Similarly, an engineered ultrasound-responsive bacterium (URB) can induce exogenous gene expression in a controlled manner *via* ultrasound. By exploiting the tissue penetration of ultrasound, bacterial gene expression can be remotely controlled with a temperature-actuated genetic switch. In testing with the immune regulatory cytokine IFN- γ , focused ultrasound-induced hyperthermia promoted IFN- γ gene expression, enhancing anti-tumor efficacy both *in vitro* and *in vivo*, offering a novel approach to bacteria-mediated tumor immunotherapy.³⁹ Du *et al.* introduced SonoBacteriaBot (DOX-PFP-PLGA@EcM), composed of doxorubicin (DOX) and perfluoro-*n*-pentane (PFP) encapsulated in polylactic acid-glycolic acid (PLGA) to form ultrasound-responsive nanodroplets. The nanodroplets are further conjugated with *E. coli* MG1655, demonstrating high tumor-targeting efficiency, controlled drug release, and ultrasound imaging capabilities. The acoustic phase change property of nanodroplets enhances ultrasound imaging while facilitating DOX release, enabling efficient tumor accumulation without organ damage upon intravenous injection.⁴⁰

Furthermore, it is possible to engineer bacteria to form nano-scale gas vesicles inside their bodies, enabling them to undergo real-time ultrasound imaging and spatiotemporally controlled lysis. Mikhail *et al.* have creatively developed a non-invasive, real-time “ear” for monitoring bacterial descent within the body using ultrasound imaging technology. By using genetic engineering, the “acoustic reporter genes” were introduced into *E. coli* and *Salmonella*, enabling the engineered bacteria to form a protein nanostructure called “gas vesicles.” In these engineered bacteria, these gas vesicles can reflect ultrasound waves, helping to detect and locate these bacteria deep within the tumor. The detection depth exceeds 10 cm, with a resolution smaller than 100 μ m, allowing for the detection of engineered bacteria with a volume density of less than

0.01%.⁶⁶ Yang *et al.* have developed genetically engineered bacteria that produce numerous sub-micron gas vesicles in the cytoplasm *via* the heterologous expression of specific gene clusters (Fig. 1C). These gas vesicles significantly enhance the acoustic sensitivity of the bacteria, enabling their manipulation by ultrasound. Using phased-array-based acoustic tweezers, these bacteria can be trapped and manipulated *in vitro* and *in vivo* using electronically steered acoustic beams, enabling controlled flow in the vasculature of live mice. This technology improves the aggregation efficiency of the bacteria in tumors, providing a platform for the *in vivo* manipulation of live cells and advancing cell-based biomedical applications.⁴¹ In addition, Wang *et al.* developed a biological targeting system using genetically engineered bacteria and multi-functional nanoparticles to treat malignant tumor. *E. coli*, which can target the tumor hypoxic microenvironment, was genetically engineered to carry an acoustic reporter gene responsible for gas vesicle (GV) formation. After the GV-producing *E. coli* (GVs-*E. coli*) colonized the tumor tissue, ultrasound imaging and focused ultrasound-acoustic synergy (FUAS) were performed. Subsequently, cationic lipid nanoparticles containing IR780 (a NIR dye), perfluoro hexane (a phase-change contrast agent), and banoxantrone dihydrochloride (AQ4N, a hypoxia-activated prodrug) were enriched in the tumor tissues *via* electrostatic adsorption, achieving targeted multimodal imaging and enhancing the curative effect of FUAS.⁴²

2.1.4 Response to radiation. Among the various therapeutic approaches, RT is widely used in clinical tumor management. However, its efficacy is significantly hindered by the development of radioresistance in tumor cells and the unavoidable radiation damage to surrounding normal tissues caused by high-energy-ionizing radiation.⁶⁷ Consequently, there is a growing interest in exploring various strategies to enhance radiotherapeutic sensitivity and minimize off-target effects. One promising approach that has emerged in recent years is the combination of bacteria-mediated therapy with RT. The distinctive biological attributes of bacteria can be harnessed to enhance tumor-related biological characteristics, thereby further augmenting the radiotherapeutic sensitivity of tumors. For instance, Pan *et al.* engineered *E. coli* MG1655 with a ClyA plasmid and modified Bi₂S₃ NPs on the bacterial surface to create a smart bacteria hybrid nanosystem (Bac@BNP) for enhanced RT sensitivity (Fig. 1D). The engineered bacteria selectively accumulated in tumor sites, transported BNPs into tumor tissues, and regulated the tumor cell cycle from a radioresistant phase to a radiosensitive phase by overexpressing bacterial ClyA. Moreover, BNPs acted as efficient radiosensitizers, generating cytotoxic ROS and inducing DNA damage in tumor tissues, which significantly enhanced RT sensitivity with low-dose X-ray irradiation.⁴³ Furthermore, Pan *et al.* developed a hybrid nanoplatform (MGTe) consisting of GTe (glutathione-decorated Te nanoparticles), fused tumor cell membranes (TM), and bacterial outer membranes (BM). This nanoplatform was designed to enhance RT sensitivity through two main mechanisms. First, under X-ray irradiation, the high-Z element tellurium in GTe can improve the production of ROS and

induce ICD in cancer cells. Second, the fusion of TM and BM is expected to amplify antitumor immune responses by maturing antigen-presenting cells (APCs) and stimulating cytotoxic T lymphocytes (CTLs).⁴⁴ The combination of these effects, namely the enhanced radiosensitivity and the triggered antitumor immunity, makes MGTe a promising approach for improving the efficacy of RT.

In addition to cell cycle regulation, various strategies have been devised to enhance radiotherapeutic efficacy, particularly by remodeling the unfavorable TME, which differs from the normal internal microenvironment in terms of weak acidity, hypoxia, and high interstitial pressure.⁶⁸ To address this issue, Huang *et al.* engineered a strain of EcN to express catalase with an NSP4 signal peptide under the tac promoter. The engineered bacteria specifically secreted catalase within the TME due to their hypoxic tropism, increasing oxygen availability and tumor susceptibility to RT. *In vivo*, these engineered bacteria combined with RT could inhibit tumor growth by up to 90%.⁴⁵ Furthermore, Zai *et al.* developed catalase-containing *E. coli* membrane nanovesicles (EMs) with outstanding protease resistance, providing long-term relief from tumor hypoxia. Even when treated with a 100-fold excess of protease, EMs exhibited higher catalase activity than free catalase. When injected into tumors after 12 hours, EMs maintained their ability to relieve hypoxia, whereas free catalase lost its activity. Meanwhile, benefiting from their immune-stimulating properties, EMs could effectively enhance RT and induce antitumor immune memory.⁴⁶

2.1.5 Response to electricity. Recent studies have shown promising results in using electric fields for cancer therapy. Compared to traditional chemotherapy and RT, electric field therapy offers advantages such as higher precision, minimal damage to normal tissues, and fewer side effects. For instance, Kirson *et al.* introduced tumor treating fields (TTFields), a method that employs low-intensity, intermediate-frequency alternating electric fields to inhibit cancer cell mitosis. Related clinical trials have demonstrated that TTFields shows significant efficacy in treating glioblastoma with fewer side effects.⁶⁹

Although there are few studies on using electric fields to regulate nanomaterial-modified engineered bacteria for cancer therapy, numerous articles demonstrate that nanomaterial-modified bacteria can enhance electron transfer efficiency and bioelectricity. For example, Wang *et al.* developed the hybrid bacteria CN32@ γ -Fe₂O₃, formed by self-assembling magnetic nanomaterials γ -Fe₂O₃ with *S. putrefaciens* CN32, showing significantly improved extracellular electron transfer and bioelectricity generation, achieving a more negative anodic peak potential and lower charge transfer resistance compared to controls.⁴⁷ Yang *et al.* used water-soluble carbon dots (CDs) synthesized from sodium naphthalene reagent and triethylamine to enhance the bioelectricity generation of *S. oneidensis* MR-1.⁴⁸ The CDs significantly boosted bacterial metabolism, electron transfer, and bioelectricity generation, achieving increases of approximately 7.34-fold in maximum current, 5.63-fold in total charge, 3.78-fold in maximum cell voltage, and 6.46-fold in power output compared to the control group.

Moreover, Reggente *et al.* engineered a polydopamine (PDA) coating on the outer membrane of *Synechocystis* sp. PCC6803 to enhance charge transfer, leading to a three-fold increase in photocurrent compared to non-coated bacteria.⁴⁹ These findings may suggest that placing nanomaterial-modified bacteria in electric fields for tumor treatment could potentially increase reactive oxygen species (ROS) production through enhanced electron transfer efficiency, possibly improving tumor-killing effects. Moreover, the introduction of bacteria might stimulate tumor immune activation, further coordinating and enhancing antitumor activity. Although this idea has not been reported in the literature, it presents a novel research direction to improve the antitumor efficacy of electrodynamic therapy.

2.2 The effect of bacteria on nanomaterials

In 1989, Matsumura and Maeda discovered the enhanced permeability and retention (EPR) effect, which triggered the development of nanomedicine.⁷⁰ Nanomaterials exhibit unique characteristics that allow them to be used in cancer treatment. For instance, nanoparticles show enhanced accumulation in tumors and have extended half-lives in the body compared to traditional small molecule drugs.⁷¹ However, despite these advantages, the aggregation, penetration, and retention of nanomaterials in the deep regions of tumor tissues remain suboptimal, thereby hindering their full therapeutic potential.⁷² To overcome these limitations, researchers have explored the combination of nanomaterials with engineered bacteria, leveraging the unique properties of both components into promising combinatorial strategies for cancer therapy (Table 2).

2.2.1 Tumor targeting. Engineered bacteria can effectively target and penetrate tumors by utilizing their self-propulsion

and guidance capabilities.^{87,88} These bacteria are guided by gradients of physiological conditions, like hypoxia or nutrient availability, enabling them to actively swim away from the tumor vasculature and penetrate deep into regions where conditions are more conducive to bacterial growth. This targeted approach allows the bacteria to specifically target tumor cells while minimizing harm to healthy tissue. Obligate anaerobes, such as *Bifidobacterium infantis*⁸⁹ and *Clostridium novyi*,⁹⁰ and facultative anaerobes, such as *Salmonella typhimurium*⁹¹ and *E. coli*,⁹² have been studied for tumor targeting. For instance, Luo *et al.* constructed a lipo-PDA-EcN hybrid system that could effectively improve the targeting of therapeutic agents and plasmids in tumor centers.²⁵ Similarly, Xing and Yin *et al.* developed an interesting nanocarrier, which utilized *Magnetospirillum magneticum* (AMB-1) bacteria containing magnetosomes susceptible to external magnetic fields. Due to the hypoxia targeting and magnetostatic motility, the hybrid system autonomously navigated and accumulated in the tumor. Following laser irradiation, the bionanosystem reached a maximum temperature of 58 °C, successfully ablating the tumor.⁷³ Moreover, Sun *et al.* introduced a bacteria-based drug delivery system, named 'Trojan bacteria', loaded with glucose polymers and photosensitive ICG silicon-nanoparticles for glioblastoma (GBM) (Fig. 2A) photothermal immunotherapy. In an orthotopic GBM mouse model, intravenously injected bacteria could effectively target GBM tissues by bypassing the blood-brain barrier (BBB).⁹³ Bacteria related components, mainly bioactive components isolated from natural bacteria, including bacterial membranes, bacterial outer membrane vesicles (OMVs), bacterial ghosts (BGs), and some other related microorganisms such as microalgae, also present a favorable tumor targeting effect. For example, Qin *et al.* leveraged OMVs derived from EcN to

Table 2 Summary of research on engineered bacteria optimizing nanomaterial performance

| Characteristic | Engineered methods | Bacteria | Mechanism | Ref. |
|-------------------------------|-----------------------------------|--|--|------|
| Tumor targeting | — | EcN | Facultative anaerobic and the aid of flagella | 25 |
| | — | Magnetostatic bacteria | Enhanced magnetic sensitivity | 73 |
| | Naturally secreted | EcN OMVs | EPR effect and ligand modification | 74 |
| | Coextrusion | Fusion membrane structure | EPR effect and tumor homing effect | 44 |
| Tumor penetration | Expressing ClyA-Hy fusion protein | Hypervesiculating <i>Escherichia coli</i> Nissle | Break down the dense extracellular matrix | 75 |
| | Expressing Hase | Attenuated <i>S. typhimurium</i> | Degrade extracellular matrix and decrease fluid pressure | 76 |
| | Naturally secreted | <i>Clostridium butyricum</i> spores | Penetrate the extracellular matrix | 77 |
| TME reprogramming | Secrete tumstain | <i>Bifidobacterium longum</i> | Induces apoptosis of tumorous vascular endothelial cells | 78 |
| | Secretes tLLO-CD105 | <i>Listeria</i> | Combats angiogenesis | 79 |
| | Deliver STAT3 siRNA | <i>Salmonella typhimurium</i> | Inhibit angiogenesis | 80 |
| | Expressing HlyE | <i>Salmonella typhimurium</i> | Induction of tumor cell apoptosis | 81 |
| | Expressing α -hemolysin | <i>Escherichia coli</i> strain γ 6212 | Kill cancer cells | 82 |
| Express oxidoreductase azurin | <i>Pseudomonas aeruginosa</i> | Triggering tumor cell apoptosis | 83 | |
| Immune activation | Express ADP-heptose | <i>Yersinia pseudotuberculosis</i> | Activate the NF- κ B signal pathway and induce Alpk1-dependent inflammation | 84 |
| | With flagellin | <i>Salmonella</i> | Activate the TLR5 signal pathway and the innate immunity | 85 |
| | Accumulate L-Arg | EcN | Activate T cells | 19 |
| | Express melanoma tumor antigens | <i>Staphylococcus aureus</i> | Activate CD4 ⁺ and CD8 ⁺ T cells | 86 |

leveraging immune cell properties for improved tumor targeting and therapeutic delivery of nanomaterial-engineered bacteria.

2.2.2 Tumor penetration. Owing to the presence of flagella, bacteria can move spontaneously and continuously to the hypoxic center of the tumor, greatly improving the effectiveness of nanomedicine. However, tumors tend to evolve ways to lock down the biological activity of these live carriers. The vectors vary in their ability to penetrate tumors, so the physical barriers mainly formed by the dense extracellular matrix in some solid tumors may hinder the penetration of certain carriers. To address this issue, Thomas *et al.* transfected EcN with plasmid-encoding cytolysin A (ClyA)-hyaluronidase fusion protein (Δ ECHy), so bacteria and their OMVs could degrade extracellular hyaluronic acid and fuse to the membrane-anchoring protein ClyA, which also has a cytolytic effect on mammalian cells to remodel the TME (Fig. 2B). Moreover, the engineered bacteria also promote anticancer agents and immune cell penetration, achieving enhanced immunotherapy and targeted therapy.⁷⁵ Kim *et al.* devised a strategy combining chemotherapy with engineered *Salmonella typhimurium* that secretes HysA protein, effectively degrading hyaluronan in the tumor extracellular matrix and inhibiting tumor growth in mouse models of pancreatic adenocarcinoma and breast cancer. This approach increased tumor apoptosis when combined with DOX or gemcitabine by reducing interstitial fluid pressure and modulating proliferation- and apoptosis-related signal pathways through decreased CD44 receptor binding.⁷⁶ Han *et al.* demonstrated an enhanced pancreatic cancer chemotherapy method utilizing a probiotic spore-based oral drug delivery system, facilitated by gut-pancreas axis translocation. Gemcitabine-loaded mesoporous silicon nanoparticles (MGEM) were covalently conjugated with extracted *Clostridium butyricum* spores, which are resistant to external stress. As the spores served as drug carriers, this PORE-MGEM system significantly increased intratumoral drug accumulation by approximately threefold compared to using MGEM alone. It also migrated upstream from the gut into pancreatic tumors, effectively suppressing tumor growth in two orthotopic pancreatic ductal adenocarcinoma (PDAC) mouse models without notable side effects.⁷⁷

2.2.3 TME reprogramming. The TME refers to the surrounding microenvironment where tumor cells exist, including surrounding vascular endothelial cells, immune cells, cancer-associated fibroblasts, bone marrow-derived inflammatory cells, various signaling molecules, and extracellular matrix.¹⁰⁰ For regulating tumor surrounding vascular endothelial cells, Wei *et al.* engineered *Bifidobacterium longum* to secrete tumstatin, a potent endogenous angiogenesis inhibitor, and designed it as a novel Tum delivery system, enabling precise tumor targeting and enhanced drug delivery. This engineered bacterium effectively inhibits tumor endothelial cell proliferation and induces tumor cell apoptosis in the CT26 tumor-bearing mouse model.⁷⁸ Similarly, Wood *et al.* developed a detoxified vaccine from monocyte proliferative *Listeria monocytogenes* that secretes the tLLO-CD105 fusion protein,

comprising cholesterol-dependent cytolysin LLO and TGF- β receptor family member endoglin (CD105), which combats angiogenesis and suppresses tumors, alleviating primary and metastatic breast cancer in mice.⁷⁹ For regulating tumor-related signaling molecules, Jia *et al.* found that a modified, detoxified strain of *Salmonella typhimurium* can deliver STAT3-specific siRNA and endostatin in an *in situ* liver cancer mouse model. The combined application of these two payloads can effectively inhibit tumor proliferation and metastasis, reduce tumor proliferation and inflammation, and decrease the number of tumor microvessels.⁸⁰

Using bacteria to produce cytotoxic proteins at tumor sites is also a way to reprogram the TME to treat cancer. This design primarily exploits the ability of bacteria to migrate to hypoxic foci within tumors and then release or secrete specific anti-tumor drugs through lysis, achieving targeted drug delivery to the tumor and inhibiting tumor growth. Jean *et al.* designed hemolysin E (HlyE)-expressing *Salmonella typhimurium*, which increased the necrosis rate of mouse mammary tumors and reduced tumor growth.⁸¹ St *et al.* showed that engineering the *Escherichia coli* strain χ 6212 (Δ asd) with *Staphylococcus aureus*-derived α -hemolysin (SAH) could cause tumor regression in 4T1 tumor-bearing mice and promote tumor necrosis.⁸² Yamada *et al.* used *Pseudomonas aeruginosa* to express low-toxicity oxidoreductase azurin, an anticancer protein whose intracellular translocation to the nucleus depends on p53. Azurin forms a complex with p53, stabilizing p53 and increasing the levels of intracellular p53 and Bax, leading to the release of mitochondrial cytochrome *c* into the cytoplasm and triggering tumor apoptosis.⁸³ In particular, Canale *et al.* utilized synthetic biology to create a modified EcN strain, which resides in tumors and converts ammonia into L-arginine continuously (Fig. 2C). This bacterial colonization elevates intertumoral L-arginine levels, boosts tumor-infiltrating T cells, and enhances the effectiveness of PD-L1 blocking antibodies in tumor elimination, demonstrating the potential of engineered microbial therapies for improving immunotherapy efficacy by altering the TME metabolically.⁹⁵

2.2.4 Activating immunity. Lipopolysaccharides (LPS), important components of the outer membrane of Gram-negative bacteria, induce inflammatory injury involving the TLR4/NF- κ B p65 inflammatory signaling pathway.¹⁰¹ After TLR4 encounters LPS, it activates the MyD88-dependent signaling pathway, triggers the NF- κ B p65 transcription response, and induces proinflammatory cytokine secretion in macrophages, DCs, and some epithelial cells.¹⁰² Zhou *et al.* conducted biochemical analyses and transposon screens in *Yersinia pseudotuberculosis*, identifying ADP-Hep as a mediator of type III secretion system-dependent NF- κ B activation and cytokine expression, which enters the host cytosol to activate NF- κ B. Activation of NF- κ B by ADP-Hep involves the ALPK1-TIFA axis, where ADP-Hep binds the N-terminal domain of ALPK1, activating TIFA *via* phosphorylation. Furthermore, ADP-heptose 7-P, transformed from HBP by host adenylyl transferases, also activates ALPK1, although to a lesser extent than ADP-Hep, inducing Alpk1-dependent inflammation during

bacterial infection, highlighting ALPK1 and ADP-Hep as a pattern recognition receptor and a potent immunomodulator, respectively.⁸⁴

As for specific immunity, Fernando *et al.* have developed an engineered probiotic EcN strain using synthetic biology methods, which can colonize tumors and continuously convert accumulated nitrogenous metabolic waste in tumors into L-arginine. The specific accumulation of L-arginine at the tumor site can promote the activation of tumor-infiltrating T cells, and thereby in combination with PD-L1 inhibitors have a powerful anti-tumor effect.¹⁹ Moreover, Chen *et al.* have engineered *Staphylococcus aureus* to stimulate CD4 and CD8 positive cells both *in vitro* and on the skin to kill melanoma without damaging the skin barrier or causing skin inflammation.⁸⁶ He *et al.* engineered *Bifidobacterium bifidum* (Bi) by covalently attaching DOX-loaded CaP/SiO₂ nanoparticles (DNPs@Bi) for tumor therapy, inducing chemotherapy and ICD within the TME *via* pH-responsive drug release (Fig. 2D). Additionally, tumor-targeting Bi enhances antigen presentation to DCs *via* Cx43-dependent gap junctions, promoting DC maturation and CTL infiltration. *In vivo* antitumor experiments demonstrated that this approach leads to prolonged survival, inhibited tumor progression, and reduced metastasis, highlighting the potential of this bacterial-driven, hypoxia-targeting delivery system for tumor chemotherapeutic immunotherapy.⁹⁶

2.3 The binding methods of engineered bacteria and nanoparticles

For effective synergistic therapy, both nanoparticles and engineered bacteria must accumulate within the tumor region. The binding methods of combining nanomedicines with engineered bacteria, such as physical, chemical, biological, and indirect methods, form the core of the synergistic anti-tumor therapy.

Physical methods such as electroporation, electrostatic adsorption, mechanical extrusion, and so on are extensively utilized to achieve effective modification of engineered bacteria with nanoparticles. Electroporation, which temporarily increases cell membrane permeability *via* an electrical field, demonstrates high efficiency in incorporating drugs and nanoparticles into bacteria. For instance, Xie *et al.* employed electroporation to integrate 5-fluorouracil and zoledronic acid into *E. coli* Nissle 1917, followed by surface decoration with gold nanorods to create a hybrid system (EcNZ/F@Au), enhancing drug delivery and tumor targeting capabilities.³² Electrostatic adsorption is a widely used method for bacterial modification, exploiting the charge interactions between negatively charged bacterial surfaces and positively charged nanoparticles.^{103,104} Furthermore, Zhong *et al.* illustrated the application of this method by modifying photosynthetic bacteria with Fe₃O₄ nanoparticles, resulting in improved tumor imaging and therapeutic efficacy.¹⁰⁵ Furthermore, mechanical extrusion with cell membranes, as demonstrated by Cao *et al.*, significantly enhances the circulation time and tumor-targeting potential of the engineered bacteria by coating with red blood cell membranes.¹⁰⁶ Collectively, these physical modification methods significantly

enhance the interaction between engineered bacteria and nanoparticles, thereby augmenting the efficacy of targeted cancer therapy.

Owing to the diverse array of functional groups present on bacterial surfaces, various chemical methods, such as Schiff base reaction, carbodiimide chemistry, *in situ* growth techniques, and so on, are employed to functionalize bacteria with nanoparticles. For instance, Luo *et al.* conjugated upconversion nanorods and gold nanorods to *Bifidobacterium breve* and *Clostridium difficile* through Schiff base reaction, facilitating hypoxia-specific delivery for tumor imaging and therapy.¹⁰⁷ Similarly, carbodiimide chemistry enables the formation of stable amide bonds between carboxyl and amine groups on bacterial surfaces and nanoparticles. Xu *et al.* demonstrated the binding of nano-photosensitizers to *Salmonella* bacteria *via* carbodiimide chemistry, enhancing their hypoxia-targeting and photothermal properties for solid tumor therapy.¹⁰⁸ Additionally, Chen *et al.* reported *in situ* biomineralization of palladium nanoparticles on *Shewanella oneidensis* MR-1, creating a photothermal bacterium that hybridizes with mitochondria-targeted metal-organic frameworks, significantly augmenting photothermal tumor therapy.¹⁰⁹

Furthermore, engineered bacteria can be effectively modified with nanoparticles using a range of biological methods, including exploiting biotin-streptavidin interactions, utilizing antigen-antibody reactions, and harnessing biofilm secretion processes. For instance, Suh *et al.* conjugated PLGA nanoparticles to *Salmonella* VNP20009 using biotin-streptavidin interaction, creating nanoscale bacteria-enabled autonomous drug delivery systems (NanoBEADS), which significantly enhanced the intratumoral transport of nanomedicine.¹¹⁰ Similarly, Chowdhury *et al.* used antigen-antibody reaction to program *Escherichia coli* with anti-PD-1 antibodies, inducing durable tumor regression and systemic antitumor immunity.¹¹¹ Additionally, Wang *et al.* described the development of carcinoma cell-mimetic bacteria (CCMB), a set of multimodal oncolytic living agents, by coating them with tumor cell-derived biofilms.¹¹² Under external stimulations, intracellularly pre-harbored bacteria are spontaneously coated with an extra membrane by forming apoptotic bodies from invaded tumor cells. This strategy significantly improves resistance, adhesion capacity, and targeting, which can be applied to cancer therapy for better targeting and retention.

Another effective modification of engineered bacteria with nanoparticles can be achieved using various indirect methods, including nanoparticle encapsulation and polymer cross-linking. For example, Wang *et al.* developed biohybrid bacterial microswimmers by encapsulating bacteria with metal-organic framework (MOF) exoskeletons.¹¹³ This method provided cytoprotection and enabled active drug delivery in harsh environments, significantly improving therapeutic efficacy in tumor treatment. Similarly, Xiong *et al.* demonstrated that a triple-layered nanogel cross-linked to bacterial surface accumulated in tumors. This nanogel, loaded with doxorubicin, selectively degraded in the bacteria-accumulated tumor environment, resulting in targeted drug release and enhanced cancer

therapy.¹¹⁴ These indirect methods enhance the stability and functionality of engineered bacteria, thereby improving the efficiency and specificity of targeted cancer therapy.

3. Nanomaterial combined engineered bacteria and cancer immunotherapy

Compared to the second-generation bacterial therapy (engineered bacteria alone) for tumor therapy, combining nanomaterials with engineered bacteria offers enhanced tumor targeting, improved imaging capabilities, and better spatiotemporal control, making it a promising approach for intelligent tumor immunotherapy. Currently, cancer immunotherapy can be broadly categorized into four major classes: immune checkpoint inhibitors, tumor vaccines, cell-based immunotherapy, and nonspecific immunomodulators (Table 3).¹¹⁵

3.1 Nanomaterial combined engineered bacteria for immune checkpoint therapy

Immune checkpoint therapy, which has emerged as a pivotal immunotherapy, targets molecules involved in coinhibitory signaling pathways, which typically help maintain immune tolerance but are frequently exploited by cancer cells to escape immune surveillance.¹³⁴ The presence of bacteria may either sensitize or inhibit the effectiveness of immune checkpoint inhibitors. In preclinical models, the effectiveness of anti-CTLA-4 therapy was shown to depend on *Bacteroides* species, as germ-free mice or mice treated with antibiotics did not respond to anti-CTLA-4 antibody; however, the response was restored by administering *Bacteroides fragilis* through gavage.¹³⁵ Similarly, the gut microbiota can modulate the effectiveness of PD-L1 inhibitors against melanoma and cutaneous tumors.^{136,137}

To address these issues, immune checkpoint inhibitors, antibodies, or plasmids can also be encapsulated in nanoparticles or modified on the surface of bacteria or OMVs, thereby achieving enhanced efficacy of immune checkpoint therapy. Abedi *et al.* developed an ultrasound-thermal responsive promoter TcI42 and a GFP reporter gene construct in EcN (Fig. 3A), which could express and release the immune checkpoints CTLA-4 and PD-L1 nanobody to suppress tumor growth.⁶⁵ Liu *et al.* proposed a dual engineered approach to modify live bacteria through genetic engineering and surface chemistry. The genetically engineered *E. coli* expressed melanin and used *in situ* polymerization of dopamine to modify the surface with anti-programmed death-1 antibodies (α -PD-1). This dual immunomodulatory approach, mediated by photothermal stimulation and checkpoint blockade, achieves a spatiotemporal release of anti-PD-1 antibodies and synergistic reprogramming of the immunosuppressive TME (Fig. 3B).¹¹⁷

Similarly, Liu *et al.* modified model antigen ovalbumin (OVA) and α -PD-1 antibodies simultaneously on the surface of bacteria using the same method. After the live bacteria reach the tumor site, the photothermal properties of polydopamine convert TAMs from the pro-tumor M2 phenotype to the anti-

tumor M1 phenotype (Fig. 3C). The OVA antigen promotes the maturation of DCs, and activates antigen-specific T cell responses, while α -PD-1 antibodies block immune checkpoints to trigger anti-tumor immunity. This synergistic immunomodulation results in an 80% survival rate in animals within 40 days, whereas mice in other groups did not survive beyond 26 days.³¹ Nie *et al.* developed a tumor-homing, magnetically controlled bacterial system for precise ICB immunotherapy. Upon *in situ* accumulation of the Fe₃O₄@lipid nanocomposite engineered *E. coli* in colon tumors, the superparamagnetic Fe₃O₄ nanoparticles allow the engineered bacteria to receive magnetic signals and convert them into heat, thereby initiating the expression of lytic proteins under the control of a heat-sensitive promoter. Subsequently, the pre-expressed anti-CD47 nanobody within the bacteria is released. The potent immunogenicity of bacterial lysates, combined with the anti-CD47 nanobody, activates innate and adaptive immune responses. The gene expression and drug release behaviors of tumor-homing bacteria can be spatiotemporally controlled *in vivo* by magnetic fields, achieving tumor-specific CD47 blockade and precise tumor immunotherapy.³⁵ Pan *et al.* designed and engineered *E. coli* expressing the target peptide LyP1 and then extracted LyP1 modified OMVs. By encapsulating the PD-1 plasmids inside, the LyP1-OMVs@PD-1 nanocarriers were obtained (Fig. 3D). Upon intravenous injection, these nanocarriers accumulate at tumor sites through the targeting ability of OMVs and are internalized into tumor cells *via* LyP1 mediation. Subsequently, the PD-1 plasmids are delivered to the cell nucleus and induce the expression of PD-1 in tumor cells. The PD-1-expressing tumor cells bind to the overexpressed PD-L1 on the surface of neighboring tumor cells, achieving self-blockade and relieving immune suppression. Meanwhile, the extracellular protein components of OMVs recruit CTL and NK cells to the tumor tissue and stimulate their secretion of IFN- γ , further enhancing the anti-tumor activity of the PD-1/PD-L1 pathway blockade. Additionally, OMVs promote the differentiation of CTL into Tcm, forming a persistent immune response.¹¹⁸

3.2 Nanomaterial combined engineered bacteria and tumor vaccine

Cancer vaccines have garnered significant attention due to their potential to counteract the immune system's tolerance to tumor-specific antigens.¹³⁸ Due to the efficient secretion or presentation of tumor-associated antigens (TAAs) on bacterial cell surfaces, bacteria have been harnessed as potential vaccine vectors to deliver antigens in diverse forms for activating antitumor immunity.¹³⁹ Furthermore, nanomaterial-modified bacteria, as a kind of new tumor vaccine, can facilitate tumor-targeted delivery of anti-tumor genes or drugs, enhance immunogenicity, enable real-time imaging, potentiate photothermal/photodynamic therapies and so on. For instance, Hu *et al.* developed an oral cancer vaccine (NP/SAL) comprising live attenuated *Salmonella* coated with VEGFR2 plasmid-loaded cationic nanoparticles through electrostatic interactions. The orally administered *Salmonella* facilitated the delivery of the

Table 3 Summary of research on nanomaterial-assisted engineered bacteria for intelligent tumor immunotherapy

| Type | Nanoparticles | Bacteria | Cargo | Tumor type | Therapeutic strategy | Ref. |
|---------------------------|--|--|---|---|---|------|
| Immune checkpoint therapy | <i>F. nucleatum</i> -mimetic nanomedicine | <i>F. nucleatum</i> | Colistin-loaded liposomes | CT26 and MC38 | Killing tumor-colonizing <i>F. nucleatum</i> and alleviating ICB inhibition | 116 |
| | Polydopamine | <i>E. coli</i> | Melanin and α -PD-1 | 4T1 | Spatiotemporal release of α -PD-1 through photothermal effect and reverses the immunosuppressive TME | 117 |
| | Polydopamine | EcN | OVA and α -PD-1 | CT26-OVA and MC38-OVA | Enhancing ICD and reversing the immunosuppressive TME | 31 |
| | Fe ₃ O ₄ @lipid nanocomposites | <i>E. coli</i> BL21 | CD47 Nb | CT26 and 4T1 | Spatiotemporal release of CD47 Nb and reactivation of macrophages | 35 |
| Tumor vaccine | OMVs | <i>E. coli</i> | LyP1 peptide and PD-1 plasmid | B16-F10 and CT26 | Self-expressing α -PD-1 and self-blocking PD-L1 | 118 |
| | Cationic nanoparticles | Attenuated <i>Salmonella</i> | VEGFR2 plasmid | B16-F10 | Inhibiting angiogenesis and activating T cells | 119 |
| | HA-IR780 NPs | <i>Vibrio vulnificus</i> | Flagellin B | TC-1 | Suppressing immune-suppressive regulatory T cells (Tregs) and increasing the fraction of CD103 ⁺ migratory DCs | 120 |
| | Artificial bacterial nanoparticle | <i>E. coli</i> | Monophosphoryl lipid A and CpG | — | Inducing greater pro-inflammatory <i>via</i> co-presentation of CpG and MPLA | 121 |
| | OMVs | <i>Bacillus</i> | CpG and OVA | E. G7 | Enhancing antigen uptake and resulting in stronger immune activation for cancer vaccines | 122 |
| | Hybrid membrane nanocarriers | <i>E. coli</i> | — | CT26, 4T1, B16, and EMT6 | Inducing DC maturation and activating splenic T cells | 123 |
| | Bacterial membrane-coated nanoparticle | <i>M. smegmatis</i> | PC7A/CpG | B78 and NXS2 | Capturing cancer neoantigens and enhancing the uptake of DCs | 124 |
| Adoptive cell therapy | Eukaryotic-prokaryotic vesicle nanoplatfom | Attenuated <i>Salmonella</i> | Poly(lactic-co-glycolic acid)-ICG | B16F10 | Stimulate the immune system and trigger the antitumor immune response | 125 |
| | — | <i>Brucella melitensis</i> 16M Δ vjbR | Combined with CAR-T | MC38 | Polarize tumor macrophages and elevate CD8 ⁺ T cells | 126 |
| | — | EcN | Heparin binding domain and CXCL16 | CT26, A20 and MC38 | Release ProCAR-Target by EcN and recruit ProCAR-T cell into the tumor site | 127 |
| Nonspecific immunity | — | <i>Staphylococcus epidermidis</i> | Melanoma non-active antigens | B16-F10-OVA | Generate tumor-specific T cells | 86 |
| | GP-ICG-SiNPs | Attenuated <i>Salmonella</i> strain VNP20009 and <i>Escherichia coli</i> 25922 | ICG | U87MG | Bypass the BBB, targeting, penetrating and thermally ablating GBM tissues | 93 |
| | OMVs | <i>Salmonella</i> | DOX | C6 glioma | Bypass the BBB, selectively recognized by neutrophils and enhance chemo/bacterial therapy | 128 |
| | OMVs | <i>E. coli</i> | Tumor antigen | MC38 and CT26 | Cross the intestinal barrier into the lamina propria and activate DC cells | 129 |
| | Au nanorod | EcN | 5-FU and macrophage phenotype regulator zoledronic acid | 4T1 | Enhance M1 polarization of macrophages and produce pro-inflammatory cytokines | 32 |
| | PLGA NPs | <i>E. coli</i> MG1655 | DOX and R848 | 4T1 | Polarizing macrophages and enhancing ICD | 130 |
| | Polydopamine | EcN | STING agonists | B16F10 | Activate the STING pathway and elevate the levels of IFN-I | 131 |
| | OMVs | <i>E. coli</i> BL21 (DE3) | IL-10 and E7 | CT26 and B16F10 | Increase systemic and intratumoral proportions of CD8 ⁺ T cells | 104 |
| | UCNPs-YS | <i>L. lactis</i> MG5267. | IFN- γ | B16F10 | Release IFN- γ , enhanced ICD and activation of T cells | 61 |
| | — | <i>Salmonella enterica</i> | TNF- α | — | Increase TNF- α in blood and promote the tumor-colonization of bacteria | 132 |
| — | <i>Salmonella</i> VNP | TNF- α Nb | B16F10 | Secrete TNF- α Nb, stimulate DC maturation and activate CD8 ⁺ T cells | 133 | |

nanoparticles into immune cells, which were readily engulfed by macrophages due to their pathogen-like characteristics. At the same time, the cationic nanoparticles facilitated the *endo*/lysosome escape of the live bacterial vector. Experimental




Fig. 3 The nanomaterial-assisted engineered bacteria and immune checkpoints. (A) FUS-activated therapeutic bacteria could express immune checkpoint inhibitors such as CTLA-4 and PD-L1 nanobodies.⁶⁵ Reproduced from ref. 65 with permission from Springer, copyright 2022. (B) An engineered *E. coli* was dually modified to concurrently carry photothermal melanin and immune checkpoint inhibitor α PD-1 by combining genetic manipulation and interfacial polymerization.¹¹⁷ Reproduced from ref. 117 with permission from John Wiley & Sons, Inc, copyright 2022. (C) The bacteria with triple immune nanoactivators are described for the creation of a tumor-resident living immunotherapeutic agent, wherein polydopamine nanoparticles, tumor-specific antigens and checkpoint-blocking antibodies are conjugated onto the bacterial surface.³¹ Reproduced from ref. 31 with permission from John Wiley & Sons, Inc, copyright 2022. (D) A novel LyP1 polypeptide-modified outer-membrane vesicle (LOMV) carrying a PD-1 plasmid is engineered to accomplish self-inhibition of PD-L1 in tumor cells.¹¹⁸ Reproduced from ref. 118 with permission from John Wiley & Sons, Inc, copyright 2022.

results demonstrated that the oral vaccines exhibited remarkable antitumor efficacy, characterized by potent T-cell activation, cytokine production, and suppression of angiogenesis in the tumor vasculature, ultimately leading to tumor necrosis.¹¹⁹ Similarly, Nie *et al.* engineered *E. coli* to establish an orally administered tumor vaccine derived from genetically engineered bacteria-based OMVs. Following oral administration (Fig. 4A), these OMVs can be produced *in situ* in the intestinal tract, carrying tumor antigens, which effectively traverse the intestinal epithelial barrier and are recognized by immune cells in the gut-associated lymphoid tissue.¹²⁸ Uthaman and colleagues combined PTT with immunotherapy by conjugating *Vibrio vulnificus* flagellin B with photoabsorber (HIF) loaded micelles. This approach demonstrated the vaccine-like properties of flagellin B, which concurrently suppressed Tregs and increased the secretion of antitumor cytokines, thereby achieving significant immunostimulatory effects in combination with PTT-produced TAAs.¹²⁰ Siefert *et al.* proposed a biomimetic strategy using antigen-loaded NPs displaying monophosphoryl lipid A (MPLA) and encapsulating CpG, functioning as an artificial bacterial vaccine platform. *In vitro* and *in vivo* experiments of this approach demonstrated enhanced CpG potency and synergistic effects with MPLA, leading to robust pro-inflammatory,

Th1-skewed cellular, and antibody-mediated responses, particularly critical for CD8⁺ T cell immunity.¹²¹ Ni *et al.* developed a demi-bacteria cancer vaccine, retaining bacterial PAMP molecules and pathogen-like physical properties inherited from its parental bacteria, essential for immune activation. By modifying *Bacillus* into a porous structure to load CpG and OVA, this optimal engineered nanoarchitecture allows multiple immunostimulatory elements to be integrated in a pattern closely resembling that of bacterial pathogens and elicits robust cellular and humoral immune responses for cancer immunotherapy.¹²² Moreover, Chen *et al.* developed a personalized cancer vaccine by modifying inactivated EcN with tumor antigens and β -glucan, an inducer of trained immunity (Fig. 4B). Upon subcutaneous injection, the vaccine (BG/OVA@EcN) accumulates at the injection sites, promoting phagocytosis by macrophages to induce trained immunity, facilitating DC maturation, T cell activation, and differentiation of M1-like macrophages in tumor tissues, ultimately demonstrating strong prophylactic and therapeutic efficacy against tumor growth through potent adaptive antitumor immunity and long-term immune memory.¹²⁹

In addition, a variety of cell membranes, including those from erythrocytes, platelets, macrophages, neutrophils, and




Fig. 4 The nanomaterial-assisted engineered bacteria and tumor vaccines. (A) The genetically engineered bacteria produced antigen-bearing outer membrane vesicles as tumor vaccines.¹²⁸ Reproduced from ref. 128 with permission from Springer, copyright 2022. (B) A personalized cancer vaccine is developed by engineering the inactivated probiotic EcN to load tumor antigens and β -glucan.¹²⁹ Reproduced from ref. 129 with permission from John Wiley & Sons, Inc, copyright 2024.

tumor cells, have been suggested to enhance the therapeutic effectiveness and safety of hybrid bacterial systems. Chen *et al.* developed a novel approach to create a hybrid membrane-based tumor vaccine using *E. coli* cytoplasmic membranes (EMs) and tumor cell membranes (TMs). TMs, obtained from surgically resected autologous tumor tissues, carried tumor neoantigens, which could trigger tumor-specific immune responses. Meanwhile, EMs acted as immune adjuvants, stimulating innate immune responses. This personalized tumor vaccine, combining antigens and adjuvants in a co-delivery hybrid membrane, showed superior efficacy in enhancing antitumor immune responses.¹²³ Navi *et al.* have constructed a multifunctional bacterial membrane-coated nanoparticle (BNP) comprised of an immune activating PC7A/CpG polyplex core coated with the bacterial membrane and imide groups enhancing antigen retrieval. This BNP can capture cancer neoantigens following RT, enhance their uptake by DCs, and facilitate their cross-presentation to stimulate an anti-tumor T cell response. In mice bearing syngeneic melanoma or neuroblastoma, BNP + RT treatment results in activation of DCs and effector T cells, marked tumor regression, and induction of tumor-specific anti-tumor immune memory. This BNP facilitates *in situ* immune recognition of a radiated tumor, enabling a novel personalized approach to cancer immunotherapy using off-the-shelf therapeutics.¹²⁴ Chen *et al.* engineered an eukaryotic-prokaryotic vesicle (EPV) nanoplatform by merging melanoma cytomembrane vesicles (CMVs) and attenuated *Salmonella* outer membrane vesicles (OMVs) together. The EPV inherits the beneficial properties of its parent components, integrating melanoma antigens with natural adjuvants to provide robust immunotherapy while allowing for easy functionalization with complementary therapeutics. In the melanoma model, the poly(lactic-co-glycolic acid)-ICG moiety (PI)-implanted EPV (PI@EPV) in combination with localized PTT exhibits synergistic antitumor effects as a therapeutic vaccine.

This eukaryotic-prokaryotic fusion strategy offers novel insights for designing tumor-immunogenic, self-adjuvating, and expandable vaccine platforms.¹²⁵

3.3 Nanomaterial combined engineered bacteria and adoptive cell therapy

Despite the success of chimeric antigen receptor (CAR)-T cells in treating hematologic malignancies, their effectiveness in targeting solid tumors has been limited. The challenge lies in the expression patterns of the tumor antigen, which makes identifying optimal targets for solid tumor therapies difficult and hinders the development of new CAR-T therapy.^{140,141} The majority of TAAs identified in solid tumors are not exclusive to tumors, increasing the risk of severe on-target, off-tumor toxicity due to cross-reactivity with proteins present in vital tissues.^{142,143} Furthermore, even if a safe target can be identified, TAAs are often expressed heterogeneously. Consequently, the application of targeted therapies exerts selection pressures, which can ultimately result in antigen-negative relapse.^{144,145}

Bacteria can be effectively integrated into chimeric antigen receptor (CAR)-T cell therapies. For instance, an attenuated bacterial strain, *Brucella melitensis*, was found to enhance proinflammatory M1 polarization of tumor macrophages and elevate the presence of CD8⁺ T cells within tumors. When administered alongside CAR-T cells in a murine model of colon cancer, this approach led to a decrease in tumor burden and a notable improvement in survival rates for the treated mice.¹²⁶ Moreover, Vincent *et al.* developed probiotic-guided CAR-T cells (ProCARs) with engineered bacteria encoding a synthetic antigen recognized by CAR-T cells (Fig. 5). The synthetic antigen facilitated communication between the bacteria and ProCARs, enabling spatiotemporal CAR activation within tumors after bacterial release. In mouse models with human tumor xenografts, ProCARs significantly slowed tumor growth, outperforming a combination of bacterial vehicles and CAR-T cells.




Fig. 5 The engineered bacteria and adoptive cell therapy. A platform of probiotic-guided CAR-T cells (ProCARs) releasing synthetic targets, which can label tumor tissue for CAR-mediated lysis *in situ*.¹²⁷ Reproduced from ref. 127 with permission from AAAS, copyright 2023.

Increased ProCAR activation was observed due to synthetic antigen presence and TLR stimulation by bacteria, highlighting the potential of programmable medicine communities.¹²⁷

Additionally, Stein-Thoeringer and colleagues have revealed the role of gut microbiota in influencing the effectiveness of CD19 CAR-T cell therapy for patients with B-cell leukemia and lymphoma. Their findings suggest that prior treatment with broad-spectrum antibiotics before administering CD19-targeted CAR-T cell therapy could lead to suboptimal efficacy and other unfavorable outcomes. In this prospective study, the largest of its kind to date, researchers tracked 172 lymphoma patients who had previously failed multiple chemotherapy treatments, from before they began CAR-T cell therapy to two years after treatment. The 20% of patients who received broad-spectrum antibiotics (high-risk antibiotics) before CAR-T cell therapy showed poor clinical prognosis compared to patients who did not receive antibiotic treatment. Patients who received broad-spectrum antibiotics before CAR-T cell therapy tended to have higher tumor burden and systemic inflammation, and these adverse pre-treatment conditions resulted in poorer outcomes of subsequent CAR-T cell therapy. Several key gut microbiotas were further identified that played a curial role, including *Bacteroides*, *Ruminococcus*, *Eubacterium*, and *Akkermansia*, with *Akkermansia* being associated with higher baseline peripheral T cell levels before patients received CAR-T cell infusion.¹⁴⁶ Therefore, it is expected that developing these identified gut microbiotas into nanohybrid systems or bacterial outer-membrane vesicle nanocarriers may help to predict and enhance the effectiveness of CAR-T therapy.

3.4 Nanomaterial combined engineered bacteria and nonspecific immunity

Nonspecific immunity encompasses tissue barriers, innate immune cells, and molecules. These tissue barriers comprise the skin, mucosal system, BBB, placental barrier, and intestinal

barrier. The skin, functioning as the body's largest immune organ, acts as a protective barrier against pathogens and initiates immune responses, while also orchestrating a series of processes, including inflammation and tissue regeneration, to facilitate wound healing.¹⁴⁷ As it is known that CD8⁺ T cells induced by *Staphylococcus epidermidis* promote skin homeostasis and expedite wound closure, Chen *et al.* constructed a strain of *Staphylococcus epidermidis* capable of expressing melanoma tumor antigens, which could stimulate antigen-specific CD8⁺ and CD4⁺ T cells both *in vitro* and on the skin, without disrupting the skin barrier or inducing skin inflammation.⁸⁶ Bacteria have the capability to bypass the BBB, suggesting their potential in addressing central nervous system diseases like glioma. Hence, Sun *et al.* introduced a bacteria-based drug delivery system, named 'Trojan bacteria', loaded with glucose polymers and photosensitive ICG silicon-nanoparticles for GBM photothermal immunotherapy. In an orthotopic GBM mouse model, the constructed Trojan bacteria could effectively penetrate GBM tissues by bypassing the BBB. Upon 808 nm laser irradiation, the photothermal effects of ICG destroy bacterial and tumor cells, while the resulting bacterial debris and TAAs trigger antitumor immune responses, leading to prolonged survival in GBM-bearing mice.⁹³ Similarly, Mi *et al.* described a bacteria-based drug delivery approach for BBB transportation, glioma targeting, and chemo-sensitization. The *Salmonella* first colonizes selectively in hypoxic tumor regions, modulating the TME and then facilitating targeted delivery of DOX *via* neutrophil-mediated transport of bacterial outer membrane vesicles (OMVs/DOX), resulting in enhanced drug accumulation in gliomas and complete tumor eradication with 100% survival in treated mice.¹⁴⁸ Furthermore, Zhu *et al.* developed the first NIR optogenetic activation platform, combining EcN with UCNPs for cancer immunotherapy (Fig. 6A). The engineered EcN, transfected with a blue-light-activated plasmid encoding flagellin B (flaB), a potent immunoactivator




Fig. 6 The nanomaterial-assisted engineered bacteria and nonspecific immunity. (A) An EcN was engineered to sense blue light and release the encoded flab, then conjugated with lanthanide UCNPs for NIR nano-optogenetic cancer immunotherapy.³⁴ Reproduced from ref. 34 with permission from John Wiley & Sons, Inc, copyright 2023. (B) The nonpathogenic EcN for tumor-targeted delivery of the STING agonist by coating biocompatible polydopamine on the bacterial surface.¹³¹ Reproduced from ref. 131 with permission from John Wiley & Sons, Inc, copyright 2023. (C) IL10-modified bacteria to extrude through the gap and self-assemble into bacterial biomimetic vesicles exposing IL10 (IL10-BBVs) on the surface with high efficiency.¹⁰⁴ Reproduced from ref. 104 with permission from John Wiley & Sons, Inc, copyright 2021. (D) A novel VNP delivery system expressing the anti-TNF- α nanobody (VNP $_{\alpha$ TNF- α) in a hypoxic tumor environment.¹³³ Reproduced from ref. 133 with permission from Springer, copyright 2023.

activating Toll-like receptor 5 (TLR5) signaling, preferentially colonizes tumors and secretes flab upon NIR photoirradiation, leading to tumor-associated macrophage repolarization and cytotoxic T cell infiltration.³⁴

Natural immune cells include macrophages, natural killer cells, and DCs, which would be activated through some signal pathway such as TLR5, TLR7/8, STING, and so on. For instance, Chen *et al.* demonstrated that the tumor-suppressive effects of *Salmonella* were significantly reduced in flagellum-deficient strains, even with higher bacterial doses, highlighting the crucial role of flagella in activating immune cells *via* the flagellin/Toll-like receptor 5 (TLR5) signaling pathway. The exogenous activation of TLR5 signaling enhanced the

therapeutic efficacy of flagellum-deficient *Salmonella* against melanoma, suggesting the potential application of TLR5 agonists in cancer immunotherapy.¹⁴⁹ Wei *et al.* loaded *E. coli* MG1655 with PLGA-R848 nanoparticles and PLGA-DOX NPs through electrostatic absorption. Leveraging their hypoxic tumor-targeting ability, the bacteria deliver these two nanoparticles to tumor sites. Afterward, the released TLR7/8 agonist R848 could reprogram TAMs into M1 macrophages alongside *E. coli*, and Dox could function as a chemotherapeutic to kill cancer cells while inducing ICD simultaneously.¹³⁰ He *et al.* used non-pathogenic EcN to efficiently load the STING agonist MSA-2 through the oxidative polymerization reaction of dopamine to construct a new biological agent PDMN for targeted

immunotherapy of tumors (Fig. 6B). This study also combined anti-PD-1 therapy to induce long-term protective immune responses in the body, thereby effectively preventing tumor recurrence and metastasis.¹³¹ More recently, Daniel *et al.* utilized non-pathogenic *E. coli* as a multifunctional platform (SYNB1891) to develop an immunotherapy for cancer treatment. This engineered bacterium can target and activate the STING pathway of APCs in tumors and activate the innate immune pathway, which can generate effective anti-tumor immunity and form immunological memory in mouse tumor models.¹⁵⁰

Innate immune molecules include complement, cytokines, cytotoxins, and enzymes. The commonly used cytokines in anti-tumor immunotherapy include interleukin-2 (IL-2), interleukin-12 (IL-12), interferon-gamma (IFN- γ), and tumor necrosis factor (TNF).¹⁵¹ These cytokines play important regulatory roles in the immune system, activating, enhancing, or inhibiting the activity of immune cells, thereby enhancing anti-tumor immune responses. Bacteria possess a diverse array of pathogen-associated molecular patterns (PAMPs), such as LPS and flagella, which act as natural immune adjuvants to stimulate antitumor immunity.¹⁵² LPS primarily engages with TLR4 on DCs and macrophages, leading to the release of IL-2, tumor necrosis factor-alpha (TNF- α), and type I interferon (IFN-I), thereby triggering a T-cell-mediated antitumor response.¹⁵³ Wei *et al.* engineered a glycol chitosan-coated *E. coli* MG1655, a nonpathogenic bacterium, by electrostatically absorbing resiquimod (R848)-loaded PLGA (PR848) onto its surface (Fig. 6C). This construct, known as Ec-PR848, was designed to actively target hypoxic tumor sites and induce polarization of TAMs. The hybrid system also led to a significant increase in the levels of TNF- α and IL-6, further enhancing immune responses.¹⁰⁴ Yan *et al.* developed a novel tumor immunotherapy technique that leverages focused ultrasound to regulate bacterial gene expression by incorporating an ultrasound-responsive gene expression circuit into tumor-targeting bacteria. This approach takes advantage of ultrasound's non-invasiveness, focusability, high tissue penetration, and acoustic-thermal conversion to regulate gene expression at the tumor site. In preclinical models, this system effectively controlled IFN- γ expression, demonstrating potential for effective immunotherapy in subcutaneous breast cancer and orthotopic liver cancer.³⁹

In addition, Leschner *et al.* found that there was a rapid surge of TNF- α in the bloodstream following intravenous injection of *Salmonella enterica serovar typhimurium* in an ectopic transplantable tumor model. This led to vascular disruption, causing a significant influx of blood into the tumors, which might be crucial in the initial stages of bacterial tumor colonization.¹³² Furthermore, Hua *et al.* developed a novel *Salmonella*-based delivery system expressing an anti-TNF- α nanobody (VNP $\alpha_{\text{TNF-}\alpha}$), which significantly enhanced delivery efficiency by continuously releasing the nanobody within the hypoxic tumor environment (Fig. 6D). VNP $\alpha_{\text{TNF-}\alpha}$ promotes antitumor immune responses by mobilizing the tumor immune response in several ways, reducing tumor angiogenesis, and stimulating the maturation of DCs, leading to

upregulation of granzyme-B and Ki67 and subsequent induction of tumor apoptosis.¹³³

3.5 Nanomaterial combined engineered bacteria and chemotherapeutic agents

In addition to the aforementioned nanomaterial-modified engineered bacteria combined with immune checkpoint inhibitors, tumor vaccines, and adoptive cell therapy, nanomaterial-modified engineered bacteria can also be synergistically combined with chemotherapeutic drugs that elicit direct or indirect antitumor immune responses. Such a therapeutic strategy not only enhances the tumor-targeting capabilities and bioavailability of chemotherapeutic drugs but also augments immune responses within the tumor microenvironment, synergistically improving antitumor efficacy.

Certain chemotherapeutic agents directly induce antitumor immune responses mainly by interacting with immune cells or modulating immune signaling pathways. When these agents are combined with nanomaterial-modified bacteria, a multi-pronged strategy is established that enhances tumor-specific targeting, improves drug bioavailability, and amplifies immune-mediated antitumor effects. For instance, Leventhal *et al.* utilized non-pathogenic *E. coli* Nissle 1917 to develop a STING agonist-producing live therapeutic (SYNB1891) using synthetic biology, which targets STING activation in phagocytic APCs and activates complementary innate immune pathways.¹⁵⁴ Similarly, Chen *et al.* improved therapeutic efficacy by using nonpathogenic *E. coli* Nissle 1917 for tumor-targeted delivery of the STING agonist MSA-2, enhancing type I interferon levels and proinflammatory cytokines, inducing DC maturation, and showing profound tumor regression in mice, especially when combined with anti-PD-1 therapy.¹³¹ Moreover, Wei *et al.* developed a cancer treatment by loading PLGA-R848 (PR848), a toll-like receptor 7/8 (TLR7/8) agonist, onto the surface of MG1655b (Ec-PR848) to induce tumor-associated macrophage polarization therapy.¹⁵⁵ The PR848/bacteria complex can effectively target tumors and polarize M2 macrophages to M1 macrophages. When supplemented with PLGA-DOX (PDOX)-induced ICD, this approach can reduce tumor immunosuppression and significantly enhance immunotherapy efficacy.

Nanomaterial-modified engineered bacteria can also be combined with chemotherapeutic agents that indirectly elicit antitumor immune responses. These agents include those that induce ICD of tumor cells, thereby activating DCs and subsequently indirectly triggering antitumor immunity. This approach harnesses the potential of engineered bacteria to enhance chemotherapeutic delivery and efficacy, while the ICD mechanism facilitates the activation of the immune system, leading to a synergistic enhancement of antitumor immunity and therapeutic outcomes. For example, Zhang *et al.* co-loaded an intelligent autophagy inhibitor hydroxychloroquine (HCQ) and chemotherapeutic drug doxorubicin (DOX) into "bulldozer" (HD@HH/EcN) driven by anoxic bacteria for PDAC chemo-immunotherapy.¹⁵⁶ The probiotic *E. coli* Nissle 1917 carries hyaluronidase-hybridized albumin nanoparticles

(HD@HH) to the PDAC tumor tissue, where the high GSH levels induce precise release of HCQ and DOX, enhancing DOX-induced ICD and improving the immunosuppressive tumor microenvironment by increasing MHC-I expression and CD8⁺ T cell recruitment. Du *et al.* proposed the ultrasound-responsive SonoBacteriaBot (DOX-PFP-PLGA@EcM), which encapsulates DOX and perfluoro-*n*-pentane (PFP) in PLGA nanodroplets, amide-bonded to the surface of *E. coli* MG1655.¹⁵⁷ This system demonstrated high tumor-targeting efficiency, controlled drug release, increased tumor ICD, and enhanced ultrasound imaging, showing significant potential for real-time monitoring and chemotherapeutic agents' delivery in clinical settings. Similarly, Liu *et al.* used a "biotin-streptavidin strategy" to combine live BCG with drug nanoparticles (PLGA-DOX) for improved bladder cancer treatment.¹⁵⁸ This system precisely targets tumor cells, enhances drug transport, and inhibits cancer progression through the synergistic effects of BCG-immunotherapy, DOX-chemotherapy, and DOX-induced ICD, showing potential for clinical translation with improved tolerance and antitumor immunity.

4. Challenges and perspectives

Immunotherapy has significantly improved cancer survival rates by reactivating the immune system to eliminate tumors. Bacteria and their derivative-based hybrid nanocarriers have shown promise due to their ability to target tumors specifically and modulate the immune system. However, despite the potential advantages of this third-generation bacterial oncology approach, there are still challenges that need to be addressed. In this section, we will discuss the strengths and limitations of utilizing bacteria and their derivative-based hybrid nanocarriers for cancer immunotherapy, as well as explore future prospects in this field.

4.1 Advantages

4.1.1 Tumor targeting. Among the current array of anti-tumor drugs, on the one hand, small molecules often exhibit potent cytotoxicity but are often plagued by low selectivity, leading to indiscriminate cell killing and potential severe adverse effects. On the other hand, monoclonal antibodies, while offering improved cancer cell selectivity, face significant challenges in tumor penetration due to physical and biological barriers, thereby limiting their overall bioavailability.¹⁵⁹ Moreover, off-target effects are inevitable, as antibodies may also recognize targets expressed on normal cells.¹⁶⁰ Oncolytic virotherapy (OVT), where wild-type (WT) or engineered viruses selectively replicate to target and eliminate tumor cells while preserving normal ones, holds promise. However, the limited distribution of oncolytic viruses within tumors, largely due to neutralization in the bloodstream, hinders their efficiency.¹⁶¹ Although most nanoparticles can passively accumulate at tumor sites *via* transcytosis¹⁶² or the enhanced permeability and retention (EPR) effect,¹⁶³ there is still not enough accumulation of them in tumor sites due to the existence of multiple

biological barriers, such as the reticuloendothelial system and mononuclear phagocyte system.

Engineered bacteria, benefiting from their inherent anaerobic and facultative anaerobic characteristics, can efficiently infiltrate the TME with minimal impact on healthy tissues. For instance, Hua *et al.* developed an engineered *Salmonella* strain that exhibits a 1000-fold increase in tumor targeting compared to the WT strain, with minimal distribution observed in the liver and kidneys.²¹ Moreover, under UV stimulation, bacteria within the cells are enclosed within apoptotic bodies released by tumor cells. Utilizing the homing ability of apoptotic bodies, a tenfold increase in the accumulation of bacteria within tumor cells has been achieved.¹⁶⁴ By leveraging the tumor-targeting and infiltrating capabilities of engineered bacteria, more efficient and specific delivery of therapeutic agents can be achieved, potentially enhancing the efficacy and safety of cancer treatment.

4.1.2 Immune activation and immune memory. The tumor immunosuppressive microenvironment poses a significant challenge to the efficacy of immunotherapy. For instance, only about 30% of patients benefit from immune checkpoint therapy, mainly those with "hot tumors" with abundant tumor-infiltrating lymphocytes (TILs).⁷³ Immune checkpoint inhibitors work by blocking the interaction between immune checkpoint molecules on T-cells and their ligands on tumor cells, which is effective in hot tumors with high T-cell infiltration and immune checkpoint molecule expression. In contrast, "cold tumors" have low levels of T-cell infiltration and immune checkpoint molecule expression, leading to T-cell exhaustion and poor response to immune checkpoint inhibitors in a large percentage of patients.¹⁶⁵ Owing to bacterial LPS and flagella, engineered bacteria have emerged as a promising approach to activate antitumor immunity and convert cold tumors into hot ones. Upon interaction with LPS, the MyD88-dependent signaling pathway was activated, leading to the induction of the NF- κ B p65 transcription response and the secretion of proinflammatory cytokines in macrophages, DCs, and certain epithelial cells.¹⁰²

In addition, nanomaterial-modified bacteria can enhance the immunostimulatory effects of bacteria by delivering additional immunomodulatory agents or by protecting the bacteria from the harsh tumor microenvironment. For example, nanoparticle-coated bacteria can deliver immune checkpoint inhibitors or other immunostimulatory molecules directly to the tumor site, thereby enhancing the activation of antitumor immunity.^{35,65,117,166}

Furthermore, in conventional cancer therapy, metastasis is the predominant cause of cancer-related morbidity and mortality, responsible for up to 90% of cancer-associated deaths,¹⁶⁷ while poor prognosis and tumor recurrence significantly contribute to diminishing cure rates.¹⁶⁸ Therefore, it is crucial to consider the optimal prognostic outcomes of effectively inhibiting tumor metastasis and recurrence when evaluating the value of a therapy. Conventional therapeutics' reliance on cytotoxic effects often leads to incomplete tumor eradication, posing a hidden risk for recurrence and metastasis,¹⁶⁹ whereas

biomaterial-derived drug carriers have been reported to educate the immune system, establishing long-lasting immune memory through fusion with tumor antigens or adjuvant molecules, especially nanoparticle-assisted engineered bacteria playing crucial roles in supporting memory cell function.^{129,170–172} Additionally, nanomaterials can improve the stability and persistence of bacteria within the tumor, allowing for prolonged immune stimulation and more effective tumor eradication.

4.1.3 Large-scale production feasibility. Unlike many traditional drugs that have achieved industrial-scale production, most existing immunotherapies are custom-tailored to a patient's specific physiological and pathological conditions. This customization often involves a complex preparation process, and occasional challenges may arise due to the unique physiological characteristics of each patient.¹⁷³ CAR-T therapy, for instance, requires the extraction of a patient's white blood cells through leukapheresis for subsequent reprogramming. However, tumor patients are often treated with chemotherapy or RT initially, which can temporarily inhibit tumor growth and lead to lymphopenia. This condition can pose challenges in collecting enough lymphocytes and harvesting T-cells with preserved functions after *in vitro* expansion.¹⁷⁴ In contrast to CAR-T therapy, the manufacturing of engineered bacterial therapeutics focused efforts on process development, scale-up, and defining critical quality attributes, particularly due to the unique characteristics of live bacteria. Developing robust fermentation and downstream processes, along with implementing predictive assays for strain activity, is essential to ensure therapeutic potency and balance biomass production with engineered circuit expression. In recent years, automated parallel bioreactor systems have expedited fermentation process development by amalgamating smaller volumes with higher throughput. This approach has facilitated larger scale production of engineered bacteria compared to traditional benchtop bioreactors, making a significant advancement in the field.¹⁷⁵

Furthermore, the cost of CAR-T therapy is much higher than that of bacterial therapy due to the complex preparation process and strict transportation and preservation conditions, rendering it unaffordable for most patients. The CAR-T therapy currently costs \$373 000 per patient, significantly higher than conventional chemotherapy agents. It is important to note that additional costs like hospitalization and supplemental drugs, not included in this figure, may add another \$150 000 to \$200 000 to the overall expense.¹⁷⁶ For bacterial tumor treatment, *in situ* synthesis and delivery of anti-tumor agents *via* bacteria offer advantages over engineered immune cells. Bacteria can produce different drugs for synergistic treatment, minimizing the need for multiple dosing and eliminating the necessity for drug purification and storage, thereby significantly reducing treatment costs.^{177,178}

4.2 Shortcomings

4.2.1 Safety. One significant distinction between bacterial hybrid systems and other drug vectors is their living nature.

This inherent property allows for large-scale expansion, but it also raises safety concerns due to the potential for excessive proliferation. Given that the immunoactive materials are not only beneficial for antitumor responses but are also prone to inducing immune hyperactivation-related side effects, including but not limited to CRS,¹⁷⁹ untargeted immune killing,¹⁸⁰ and pathogen-associated inflammation,¹⁸¹ their use may exacerbate the challenges faced by tumor patients already battling autoimmune diseases and poor health. Crucially, due to their biocompatibility, the majority of these bioactive carriers are likely to evade body clearance easily, posing the risk of unwanted proliferation, mutation, and long-term toxicity.¹⁸² The intricate compositions of nanomaterial-assisted engineered bacteria represent a secondary trigger for potential side effects. While the bioactive vectors show improved tumor selectivity, sporadic off-target distribution can still occur due to the nonspecific nature of the tumor target. To address this, surface engineering of bacteria has emerged as a promising solution by significantly decreasing the infection potential and non-specific colonization of bacteria at normal organs, thereby achieving high *in vivo* biosafety.^{183–185}

4.2.2 Efficacy. The fundamental features of NPs, encompassing their shape, size, and charge, together with their interaction with bacteria, exert a substantial impact on hybrid bacterial systems. In general, bacteria modified with nonspherical nanomaterials exhibit a superior ability to evade the immune system compared to those modified with spherical nanomaterials, thereby circumventing the rapid clearance by macrophages.¹⁸⁶ Moreover, the size and quantity of NPs transported by bacteria also influence the targeted migration, metabolism, and proliferation of bacteria. Therefore, various factors should be taken into account to enhance the efficacy of hybrid bacterial systems. Additionally, certain therapeutic approaches such as PDT and RT necessitate external physical stimuli. Exposing bacteria to exogenous physical stimuli, such as laser, ultrasound, or radiation, may diminish their intrinsic therapeutic efficacy and hinder their typical division and proliferation.

4.2.3 Stability of manufacturing. For a therapeutic formulation, ensuring stability and quality is essential for its widespread clinical application. As most of these bioactive vectors like bacterial hybrid systems consist of various biological components and are still in the early stages of research and application, there are currently no reliable or standardized guidelines to ensure their consistency and repeatability in large-scale manufacturing.¹⁸⁷ The lack of quality assurance complicates the determination of drug dosages. This is one of the reasons why only a few cell therapies have been approved for clinical use to date. The majority of clinical oncology treatments still rely on traditional genotoxic therapies like chemotherapy and RT, as their dosages and procedures are at least guided by reliable standards.

Even in laboratory research, stability and quality concerns such as inconsistent drug loading, therapeutic concentration, and antitumor efficacy are the common challenges faced by scientists. In cancer therapies, most of the bacterial vectors are

considered drug carriers for delivering small molecules or nanomaterials through surface modification, gene technology, membrane coating, *etc.* Regardless of the method used for drug loading, there is no assurance that the loading efficiency of the resulting product is consistent across each preparation. This results in medication being cumbersome and unpredictable. However, the excessive injection of empty bacterial vectors, lacking successful drug loading, may result in side effects, while isolating and purifying vectors with successful drug loading remains challenging. Furthermore, the proliferative capacity of live bacteria enables large-scale expansion but also introduces uncertainty regarding product quality, as the density of mechanically combined therapeutics may decrease with bacteria division.¹⁸⁸ Hence, after achieving consistent production, overcoming the challenge of maintaining an effective concentration of drugs both *in vitro* and *in vivo* is a hurdle that requires research breakthroughs in the future. Finally, apart from the loaded cargos, the nanomaterial-assisted engineered bacteria also play a role in the tumoricidal capacity of these antitumor therapies. However, tumors have a tendency to develop mechanisms to block the biological activity of these live carriers. The vectors differ in their capacity to penetrate tumors, with physical barriers primarily formed by the dense extracellular matrix in certain solid tumors potentially hindering the penetration of carriers with limited infiltration ability.¹⁸⁹

5. Conclusion

In conclusion, we have provided an overview of recent advancements in nanomaterial combined engineered bacteria for intelligent cancer immunotherapy. The hybrid system's superior immunogenicity, tumor-targeting capabilities, and spatio-temporal control offer promising strategies for future cancer treatments. However, it is crucial to address challenges such as immune overactivation, cytotoxicity, production stability, and cost-effectiveness of them. By combining with other therapies such as PTT, PDT, chemotherapy, and RT, these nanomaterial combined engineered bacterial systems have the potential to counteract the immunosuppressive TME and play a pivotal and indispensable role in cancer immunotherapy in the future.

Author contributions

S. Qin and Prof. J. Yang designed the topic and outline of the review; S. Qin wrote the original draft; G. He and Prof. J. Yang reviewed and edited the manuscript.

Data availability

No new data were generated or analyzed in support of this research.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This study was funded by the National Natural Science Foundation of China (82202347) and the Supporting project of Nanjing University of Chinese Medicine to NSFC (XPT82202347). The Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine), Jiangsu Key Discipline Construction Fund of the 14th Five-Year Plan (Biology).

References

- 1 H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, *CA-Cancer J. Clin.*, 2021, **71**, 209–249.
- 2 L. Galluzzi, J. M. Bravo-San Pedro, S. Demaria, S. C. Formenti and G. Kroemer, *Nat. Rev. Clin. Oncol.*, 2017, **14**, 247–258.
- 3 O. Strobel, J. Neoptolemos, D. Jager and M. W. Buchler, *Nat. Rev. Clin. Oncol.*, 2019, **16**, 11–26.
- 4 I. F. Tannock, *Lancet*, 1998, **351**(Suppl 2), SII9-16.
- 5 M. O. Palumbo, P. Kavan, W. H. Miller, Jr., L. Panasci, S. Assouline, N. Johnson, V. Cohen, F. Patenaude, M. Pollak, R. T. Jago and G. Batist, *Front. Pharmacol.*, 2013, **4**, 57.
- 6 S. K. Vinod and E. Hau, *Respirology*, 2020, **25**(Suppl 2), 61–71.
- 7 E. Pylaeva, S. Lang and J. Jablonska, *Front. Immunol.*, 2016, **7**, 629.
- 8 W. J. Lesterhuis, A. Bosco, M. J. Millward, M. Small, A. K. Nowak and R. A. Lake, *Nat. Rev. Drug Discovery*, 2017, **16**, 264–272.
- 9 L. Chen, T. Xie, B. Wei and D. L. Di, *Oncol. Lett.*, 2022, **24**, 358.
- 10 S. Felgner, D. Kocijancic, M. Frahm and S. Weiss, *Int. J. Microbiol.*, 2016, **2016**, 8451728.
- 11 C. Jimenez-Jimenez, V. M. Moreno and M. Vallet-Regi, *Nanomaterials*, 2022, **12**, 288.
- 12 H. C. Nauts, W. E. Swift and B. L. Coley, *Cancer Res.*, 1946, **6**, 205–216.
- 13 E. F. McCarthy, *Iowa Orthop. J.*, 2006, **26**, 154–158.
- 14 G. S. Kienle, *Glob Adv. Healthcare Med.*, 2012, **1**, 92–100.
- 15 N. S. Forbes, *Nat. Rev. Cancer*, 2010, **10**, 785–794.
- 16 V. D. Joshi, D. V. Kalvakolanu and A. S. Cross, *FEBS Lett.*, 2003, **555**, 180–184.
- 17 B. F. Sieow, K. S. Wun, W. P. Yong, I. Y. Hwang and M. W. Chang, *Trends Cancer*, 2021, **7**, 447–464.
- 18 M. G. Kramer, M. Masner, F. A. Ferreira and R. M. Hoffman, *Front. Microbiol.*, 2018, **9**, 16.
- 19 F. P. Canale, C. Basso, G. Antonini, M. Perotti, N. Li, A. Sokolovska, J. Neumann, M. J. James, S. Geiger, W. Jin, J. P. Theurillat, K. A. West, D. S. Leventhal, J. M. Lora, F. Sallusto and R. Geiger, *Nature*, 2021, **598**, 662–666.
- 20 C. R. Gurbatri, I. Lia, R. Vincent, C. Coker, S. Castro, P. M. Treuting, T. E. Hinchliffe, N. Arpaia and T. Danino, *Sci. Transl. Med.*, 2020, **12**, eaax0876.

- 21 L. Liu, X. Liu, W. Xin, L. Zhou, B. Huang, C. Han, Z. Cao and Z. Hua, *Signal Transduction Targeted Ther.*, 2023, **8**, 134.
- 22 J. Chen, X. Li, Y. Liu, T. Su, C. Lin, L. Shao, L. Li, W. Li, G. Niu, J. Yu, L. Liu, M. Li, X. Yu and Q. Wang, *Microb. Biotechnol.*, 2021, **14**, 2130–2139.
- 23 Q. W. Chen, J. Y. Qiao, X. H. Liu, C. Zhang and X. Z. Zhang, *Chem. Soc. Rev.*, 2021, **50**, 12576–12615.
- 24 J. Yu, B. Zhou, S. Zhang, H. Yin, L. Sun, Y. Pu, B. Zhou, Y. Sun, X. Li, Y. Fang, L. Wang, C. Zhao, D. Du, Y. Zhang and H. Xu, *Nat. Commun.*, 2022, **13**, 7903.
- 25 W. Luo, Z. Zhang, D. Zhou, Y. Jiang, J. Yang, B. He, H. Yu and Y. Song, *Nano Lett.*, 2023, **23**, 8081–8090.
- 26 W. Lin, Y. Liu, J. Wang, Z. Zhao, K. Lu, H. Meng, R. Luoliu, X. He, J. Shen, Z. W. Mao and W. Xia, *Angew. Chem., Int. Ed.*, 2023, **62**, e202310158.
- 27 Z. Yang, Y. Zhu, Z. Dong, Y. Hao, C. Wang, Q. Li, Y. Wu, L. Feng and Z. Liu, *Biomaterials*, 2022, **281**, 121332.
- 28 F. M. Chen, Z. S. Zang, Z. Chen, L. Cui, Z. G. Chang, A. Q. Ma, T. Yin, R. J. Liang, Y. T. Han, Z. H. Wu, M. B. Zheng, C. L. Liu and L. T. Cai, *Biomaterials*, 2019, **214**, 119226.
- 29 Q. W. Chen, X. H. Liu, J. X. Fan, S. Y. Peng, J. W. Wang, X. N. Wang, C. Zhang, C. J. Liu and X. Z. Zhang, *Adv. Funct. Mater.*, 2020, **30**, 1909806.
- 30 L. Y. Wang, W. J. Qin, W. X. Xu, F. Huang, X. C. Xie, F. Wang, L. X. Ma and C. Zhang, *Small*, 2021, **17**, 2102932.
- 31 J. J. Li, Q. Xia, H. Y. Guo, Z. Z. Fu, Y. Liu, S. S. Lin and J. Y. Liu, *Angew. Chem., Int. Ed.*, 2022, **61**, e202202409.
- 32 S. Z. Xie, P. Zhang, Z. L. Zhang, Y. Liu, M. H. Chen, S. Li and X. H. Li, *Acta Biomater.*, 2021, **131**, 172–184.
- 33 L. L. Liu, H. M. He, Z. Y. Luo, H. M. Zhou, R. J. Liang, H. Pan, Y. F. Ma and L. T. Cai, *Adv. Funct. Mater.*, 2020, **30**, 1910176.
- 34 X. Q. Zhu, S. H. Chen, X. W. Hu, L. J. Zhao, Y. Q. Wang, J. Z. Huang, J. W. Chen, Y. Z. Qiu, X. F. Zhang, M. D. Wang, X. L. Yang, Y. Zhang and Y. H. Zhu, *Adv. Mater.*, 2023, **35**, 2207198.
- 35 X. T. Ma, X. L. Liang, Y. Li, Q. Q. Feng, K. M. Cheng, N. N. Ma, F. Zhu, X. J. Guo, Y. L. Yue, G. N. Liu, T. J. Zhang, J. Liang, L. Ren, X. Zhao and G. J. Nie, *Nat. Commun.*, 2023, **14**, 1606.
- 36 H. T. Chen, Y. Z. Li, Y. J. Wang, P. Ning, Y. J. Shen, X. Y. Wei, Q. S. Feng, Y. L. Liu, Z. G. Li, C. Xu, S. Y. Huang, C. J. Deng, P. Wang and Y. Cheng, *ACS Nano*, 2022, **16**, 6118–6133.
- 37 D. N. Zhong, W. L. Li, Y. C. Qi, J. He and M. Zhou, *Adv. Funct. Mater.*, 2020, **30**, 1910395.
- 38 J. H. Xing, T. Yin, S. M. Li, T. T. Xu, A. Q. Ma, Z. Chen, Y. M. Luo, Z. Y. Lai, Y. N. Lv, H. Pan, R. J. Liang, X. Y. Wu, M. B. Zheng and L. T. Cai, *Adv. Funct. Mater.*, 2021, **31**, 2008262.
- 39 Y. H. Chen, M. Du, Z. Yuan, Z. Y. Chen and F. Yan, *Nat. Commun.*, 2022, **13**, 4468.
- 40 M. Du, T. Wang, R. J. Feng, P. H. Zeng and Z. Y. Chen, *Front. Bioeng. Biotechnol.*, 2023, **11**, 1144963.
- 41 Y. Yang, Y. Z. Yang, D. Y. Liu, Y. Y. Wang, M. Q. Lu, Q. Zhang, J. Q. Huang, Y. C. Li, T. Ma, F. Yan and H. R. Zheng, *Nat. Commun.*, 2023, **14**, 3297.
- 42 Y. T. Wang, Y. Tang, Y. Du, L. Lin, Z. Zhang, X. Ou, S. Chen, Q. Wang and J. Z. Zou, *Acta Biomater.*, 2022, **150**, 337–352.
- 43 P. Pan, X. Dong, Y. Chen, X. Zeng and X. Z. Zhang, *ACS Nano*, 2022, **16**, 801–812.
- 44 P. Pan, X. Dong, Y. Chen, J. J. Ye, Y. X. Sun and X. Z. Zhang, *Biomaterials*, 2022, **289**, 121810.
- 45 C. Y. Huang, F. B. Wang, L. Liu, W. Jiang, W. Liu, W. Ma and H. Zhao, *Adv. Healthcare Mater.*, 2021, **10**, 2002207.
- 46 W. J. Zai, L. Kang, T. J. Dong, H. R. Wang, L. N. Yin, S. J. Gan, W. J. Lai, Y. B. Ding, Y. Q. Hu and J. H. Wu, *ACS Nano*, 2021, **15**, 15381–15394.
- 47 X. Wang, Z. Shi, Z. Wang and X. Wu, *Materials*, 2024, **17**, 1501.
- 48 C. Yang, H. Aslan, P. Zhang, S. Zhu, Y. Xiao, L. Chen, N. Khan, T. Boesen, Y. Wang, Y. Liu, L. Wang, Y. Sun, Y. Feng, F. Besenbacher, F. Zhao and M. Yu, *Nat. Commun.*, 2020, **11**, 1379.
- 49 M. Reggente, C. Roullier, M. Mouhib, P. Brandl, H. X. Wang, S. Tacconi, F. Mura, L. Dini, R. Labarile, M. Trotta, F. Fischer and A. A. Boghossian, *Nano Res.*, 2024, **17**, 866–874.
- 50 H. P. Lee and A. K. Gaharwar, *Adv. Sci.*, 2020, **7**, 2000863.
- 51 M. Overchuk, R. A. Weersink, B. C. Wilson and G. Zheng, *ACS Nano*, 2023, **17**, 7979–8003.
- 52 G. Hannon, F. L. Tansi, I. Hilger and A. Prina-Mello, *Adv. Therap.*, 2021, **4**, 2000267.
- 53 W. Luo, Z. B. Zhang, D. T. Zhou, Y. T. Jiang, J. J. Yang, B. S. He, H. J. Yu and Y. J. Song, *Nano Lett.*, 2023, **23**, 8081–8090.
- 54 J. Li, L. S. Xie, B. Li, C. Yin, G. H. Wang, W. Sang, W. X. Li, H. Tian, Z. Zhang, X. J. Zhang, Q. L. Fan and Y. L. Dai, *Adv. Mater.*, 2021, **33**, 2008481.
- 55 M. Przygoda, D. Bartusik-Aebischer, K. Dynarowicz, G. Cieslar, A. Kawczyk-Krupka and D. Aebischer, *Int. J. Mol. Sci.*, 2023, **24**, 16890.
- 56 M. L. Song, T. Liu, C. R. Shi, X. Z. Zhang and X. Y. Chen, *ACS Nano*, 2016, **10**, 633–647.
- 57 M. Gao, C. Liang, X. J. Song, Q. Chen, Q. T. Jin, C. Wang and Z. Liu, *Adv. Mater.*, 2017, **29**, 1701429.
- 58 H. R. Wang, Y. Chao, J. J. Liu, W. W. Zhu, G. L. Wang, L. G. Xu and Z. G. Liu, *Biomaterials*, 2018, **181**, 310–317.
- 59 H. J. Yang, Y. Qiao, Z. Chang, H. Deng, P. He and H. S. Zhou, *Adv. Mater.*, 2020, **32**, 2004240.
- 60 Y. Y. Zhang, X. Xue, M. X. Fang, G. J. Pang, Y. J. Xing, X. Y. Zhang, L. Y. Li, Q. Chen, Y. X. Wang, J. Chang, P. Q. Zhao and H. J. Wang, *ACS Appl. Mater. Interfaces*, 2022, **41**, 46351–46361.
- 61 C. S. Wu, M. H. Cui, L. Cai, C. Chen, X. H. Zhu, Y. H. Wu, J. L. Liu, H. J. Wang and Y. Zhang, *ACS Appl. Mater. Interfaces*, 2022, **14**, 13094–13106.
- 62 N. A. Valdez-Cruz, L. Caspeta, N. O. Pérez, O. T. Ramírez and M. A. Trujillo-Roldán, *Microb. Cell Fact.*, 2010, **9**, 1–16.

- 63 M. H. Cui, T. Sun, S. B. Li, H. Z. Pan, J. Liu, X. Y. Zhang, L. Y. Li, S. S. Li, C. Y. Wei, C. Z. Yu, C. Yang, N. Ma, B. L. Ma, S. J. Lu, J. Chang, W. W. Zhang and H. J. Wang, *Cell Rep.*, 2021, **36**, 567.
- 64 Z. Izadifar, Z. Izadifar, D. Chapman and P. Babyn, *J. Clin. Med.*, 2020, **9**, 460.
- 65 M. H. Abedi, M. S. Yao, D. R. Mittelstein, A. Bar-Zion, M. B. Swift, A. Lee-Gosselin, P. Barturen-Larrea, M. T. Buss and M. G. Shapiro, *Nat. Commun.*, 2022, **13**, 1585.
- 66 R. W. Bourdeau, A. Lee-Gosselin, A. Lakshmanan, A. Farhadi, S. R. Kumar, S. P. Nety and M. G. Shapiro, *Nature*, 2018, **553**, 86–206.
- 67 M. Baumann, M. Krause, J. Overgaard, J. Debus, S. M. Bentzen, J. Daartz, C. Richter, D. Zips and T. Bortfeld, *Nat. Rev. Cancer*, 2016, **16**, 234–249.
- 68 S. Gao, X. Y. Yang, J. K. Xu, N. Qiu and G. X. Zhai, *ACS Nano*, 2021, **15**, 12567–12603.
- 69 E. D. Kirson, Z. Gurvich, R. Schneiderman, E. Dekel, A. Itzhaki, Y. Wasserman, R. Schatzberger and Y. Palti, *Cancer Res.*, 2004, **64**, 3288–3295.
- 70 H. Maeda, *J. Perinat. Med.*, 2021, **11**, 229.
- 71 V. Ejigah, O. Owoseni, P. Bataille-Backer, O. D. Ogundipe, F. A. Fisusi and S. K. Adesina, *Polymers*, 2022, **14**, 2601.
- 72 W. Q. Yu, C. Hu and H. L. Gao, *ACS Appl. Bio. Mater.*, 2020, **3**, 5455–5462.
- 73 Q. L. Li, H. T. Chen, X. Y. Feng, C. C. Yu, F. Feng, Y. H. Chai, P. Lu, T. Song, X. Y. Wang and L. Yao, *Small*, 2019, **15**, 1902626.
- 74 J. Q. Qin, T. Yang, J. Y. Li, G. T. Zhan, X. Li, Z. H. Wei, Z. X. Chen, W. X. Zheng, H. B. Chen, X. L. Yang and L. Gan, *Nano Today*, 2022, **460**, 101591.
- 75 S. C. Thomas, T. Madaan, N. S. Kamble, N. A. Siddiqui, G. M. Pualetti and N. Kotagiri, *Adv. Healthcare Mater.*, 2022, **11**, 2101487.
- 76 J. S. Kim, J. E. Park, S. H. Choi, S. W. Kang, J. H. Lee, J. S. Lee, M. Shin and S. H. Park, *J. Controlled Release*, 2023, **355**, 199–210.
- 77 Z. Y. Han, Q. W. Chen, Z. J. Fu, S. X. Cheng and X. Z. Zhang, *Nano Lett.*, 2022, **21**, 8608–8617.
- 78 C. Wei, A. Y. Xun, X. X. Wei, J. Yao, J. Y. Wang, R. Y. Shi, G. H. Yang, Y. X. Li, Z. L. Xu, M. G. Lai, R. Zhang, L. S. Wang and W. S. Zeng, *Technol. Cancer Res. Treat.*, 2016, **15**, 498–508.
- 79 L. M. Wood, Z. K. Pan, P. Guirnalda, P. Tsai, M. Seavey and Y. Paterson, *Cancer Immunol. Immunother.*, 2011, **60**, 931–942.
- 80 H. J. Jia, Y. Li, T. S. Zhao, X. Li, J. D. Hu, D. Yin, B. F. Guo, D. J. Kopecko, X. J. Zhao, L. Zhang and D. Xu, *Cancer Immunol. Immunother.*, 2012, **61**, 1977–1987.
- 81 R. M. Ryan, J. Green, P. J. Williams, S. Tazzyman, S. Hunt, J. H. Harmey, S. C. Kehoe and C. E. Lewis, *Gene Ther.*, 2009, **16**, 329–339.
- 82 A. T. St Jean, C. A. Swofford, J. T. Panteli, Z. J. Brentzel and N. S. Forbes, *Mol. Therapy*, 2014, **22**, 1266–1274.
- 83 T. Yamada, M. Goto, V. Punj, O. Zaborina, M. L. Chen, K. Kimbara, D. Majumdar, E. Cunningham, T. K. D. Gupta and A. M. Chakrabarty, *Proc. Natl. Acad. Sci. U. S. A.*, 2002, **99**, 14098–14103.
- 84 P. Zhou, Y. She, N. Dong, P. Li, H. B. He, A. Borio, Q. C. Wu, S. Lu, X. J. Ding, Y. Cao, Y. Xu, W. Q. Gao, M. Q. Dong, J. J. Ding, D. Wang, A. Zamyatina and F. Shao, *Nature*, 2018, **561**, 122–126.
- 85 J. X. Chen, Y. T. Qiao, G. Chen, C. J. Chang, H. Dong, B. Tang, X. W. Cheng, X. F. Liu and Z. C. Hua, *Acta Pharm. Sin. B*, 2021, **11**, 3165–3177.
- 86 Y. E. Chen, D. Bousbaine, A. Veinbachs, K. Atabakhsh, A. Dimas, V. K. Yu, A. S. Zhao, N. J. Enright, K. Nagashima, Y. Belkaid and M. A. Fischbach, *Science*, 2023, **380**, 203–210.
- 87 C. R. Gurbatri, N. Arpaia and T. Danino, *Science*, 2022, **378**, 858–863.
- 88 Y. Ding, Y. Wang and Q. Hu, *Exploration*, 2022, **2**, 20210106.
- 89 C. Yi, Y. Huang, Z. Y. Guo and S. R. Wang, *Acta Pharm. Sin.*, 2005, **26**, 629–634.
- 90 L. Van Mellaert, S. Barbé and J. Anné, *Trends Microbiol.*, 2006, **14**, 190–196.
- 91 D. H. Thamm, I. D. Kurzman, I. King, Z. J. Li, M. Sznol, R. R. Dubielzig, D. M. Vail and E. G. MacEwen, *Clin. Cancer Res.*, 2005, **11**, 4827–4834.
- 92 J. Stritzker, S. Weibel, P. J. Hill, T. A. Oelschlaeger, W. Goebel and A. A. Szalay, *Int. J. Med. Microbiol.*, 2007, **297**, 151–162.
- 93 R. Sun, M. Z. Liu, J. P. Lu, B. B. Chu, Y. M. Yang, B. Song, H. Y. Wang and Y. He, *Nat. Commun.*, 2022, **13**, 5127.
- 94 K. Kuerban, X. W. Gao, H. Zhang, J. Y. Liu, M. X. Dong, L. N. Wu, R. H. Ye, M. Q. Feng and L. Ye, *Acta Pharm. Sin. B*, 2020, **10**, 1534–1548.
- 95 F. P. Canale, C. Basso, G. Antonini, M. Perotti, N. Li, A. Sokolovska, J. Neumann, M. J. James, S. Geiger, W. J. Jin, J. P. Theurillat, K. A. West, D. S. Leventhal, J. M. Lora, F. Sallusto and R. Geiger, *Nature*, 2021, **598**, 662–666.
- 96 T. T. He, L. Wang, S. Q. Gou, L. Lu, G. H. Liu, K. Wang, Y. L. Yang, Q. J. Duan, W. B. Geng, P. Zhao, Z. Luo and K. Y. Cai, *ACS Nano*, 2023, **17**, 9953–9971.
- 97 L. Liu, W. Xin, Q. Li, B. Huang, T. Yin, S. Hua, C. Yang, C. Chen, C. Han and Z. Hua, *Adv. Sci.*, 2023, **10**, e2301835.
- 98 M. Li, S. Li, H. Zhou, X. Tang, Y. Wu, W. Jiang, Z. Tian, X. Zhou, X. Yang and Y. Wang, *Nat. Commun.*, 2020, **11**, 1126.
- 99 S. Z. Xie, P. Zhang, Z. L. Zhang, Y. Liu, M. H. Chen, S. Li and X. H. Li, *Acta Biomater.*, 2021, **131**, 172–184.
- 100 K. E. de Visser and J. A. Joyce, *Cancer Cell*, 2023, **41**, 374–403.
- 101 S. M. Opal, P. J. Scannon, J. L. Vincent, M. White, S. F. Carroll, J. E. Palardy, N. A. Parejo, J. P. Pribble and J. H. Lemke, *J. Infect. Dis.*, 1999, **180**, 1584–1589.
- 102 R. Medzhitov, *Nature*, 2008, **454**, 428–435.
- 103 S. Ding, Z. Liu, C. Huang, N. Zeng, W. Jiang and Q. Li, *ACS Appl. Mater. Interfaces*, 2021, **13**, 10564–10573.

- 104 L. Q. Hua, Z. Q. Yang, W. R. Li, Q. S. Zhang, Z. L. Ren, C. Ye, X. Zheng, D. Li, Q. Long, H. M. Bai, W. J. Sun, X. Yang, P. Zheng, J. R. He, Y. J. Chen, W. W. Huang and Y. B. Ma, *Adv. Mater.*, 2021, **33**, 2103923.
- 105 D. N. Zhong, W. L. Li, Y. C. Qi, J. He and M. Zhou, *Adv. Funct. Mater.*, 2020, **30**, 1910395.
- 106 Z. Cao, S. Cheng, X. Wang, Y. Pang and J. Liu, *Nat. Commun.*, 2019, **10**, 3452.
- 107 C. H. Luo, C. T. Huang, C. H. Su and C. S. Yeh, *Nano Lett.*, 2016, **16**, 3493–3499.
- 108 F. Chen, Z. Zang, Z. Chen, L. Cui, Z. Chang, A. Ma, T. Yin, R. Liang, Y. Han, Z. Wu, M. Zheng, C. Liu and L. Cai, *Biomaterials*, 2019, **214**, 119226.
- 109 Q. W. Chen, X. H. Liu, J. X. Fan, S. Y. Peng, J. W. Wang, X. N. Wang, C. Zhang, C. J. Liu and X. Z. Zhang, *Adv. Funct. Mater.*, 2020, **30**, 1909806.
- 110 S. Suh, A. Jo, M. A. Traore, Y. Zhan, S. L. Coutermarsh-Ott, V. M. Ringel-Scaia, I. C. Allen, R. M. Davis and B. Behkam, *Adv. Sci.*, 2019, **6**, 1801309.
- 111 S. Chowdhury, S. Castro, C. Coker, T. E. Hinchliffe, N. Arpaia and T. Danino, *Nat. Med.*, 2019, **25**, 1057–1063.
- 112 X. Wang, Z. Cao, M. Zhang, L. Meng, Z. Ming and J. Liu, *Sci. Adv.*, 2020, **6**, eabb1952.
- 113 Y. Li, S. Tang, Z. Cong, D. Lu, Q. Yang, Q. Chen, X. Zhang and S. Wu, *Mater. Today Chem.*, 2022, **23**, 100609.
- 114 M. H. Xiong, Y. Bao, X. J. Du, Z. B. Tan, Q. Jiang, H. X. Wang, Y. H. Zhu and J. Wang, *ACS Nano*, 2013, **7**, 10636–10645.
- 115 H. Dai, Q. Fan and C. Wang, *Exploration*, 2022, **2**, 20210157.
- 116 L. F. Chen, R. Zhao, J. J. Shen, N. H. Liu, Z. X. Zheng, Y. Miao, J. F. Zhu, L. Zhang, Y. Y. Wang, H. P. Fang, J. Zhou, M. Y. Li, Y. Yang, Z. Liu and Q. Chen, *Adv. Mater.*, 2023, **35**, 2306281.
- 117 L. Wang, Z. P. Cao, M. M. Zhang, S. S. Lin and J. Y. Liu, *Adv. Mater.*, 2022, **34**, 2106669.
- 118 J. M. Pan, X. L. Li, B. F. Shao, F. N. Xu, X. H. Huang, X. Guo and S. B. Zhou, *Adv. Mater.*, 2022, **34**, 2106307.
- 119 Q. L. Hu, M. Wu, C. Fang, C. Y. Cheng, M. M. Zhao, W. H. Fang, P. K. Chu, Y. Ping and G. P. Tang, *Nano Lett.*, 2015, **15**, 2732–2739.
- 120 S. Uthaman, S. Pillarisetti, H. S. Hwang, A. P. Mathew, K. M. Huh, J. H. Rhee and I. K. Park, *ACS Appl. Mater. Interfaces*, 2021, **13**, 4844–4852.
- 121 A. L. Siefert, M. J. Caplan and T. M. Fahmy, *Biomaterials*, 2016, **97**, 85–96.
- 122 D. Z. Ni, S. Qing, H. Ding, H. Yue, D. Yu, S. Wang, N. N. Luo, Z. G. Su, W. Wei and G. H. Ma, *Adv. Sci.*, 2017, **4**, 1700083.
- 123 L. Chen, H. Qin, R. F. Zhao, X. Zhao, L. R. Lin, Y. Che, Y. X. Lin, Y. Li, Y. T. Qin, Y. Y. Li, S. L. Liu, K. M. Cheng, H. Q. Chen, J. Shi, G. J. Anderson, Y. Wu, Y. L. Zhao and G. J. Nie, *Sci. Transl. Med.*, 2021, **13**, eabc2816.
- 124 R. B. Patel, M. Z. Ye, P. M. Carlson, A. Jaquish, L. Zangl, B. Ma, Y. Y. Wang, I. Arthur, R. S. Xie, R. J. Brown, X. Wang, R. Sriramaneni, K. Kim, S. Q. Gong and Z. S. Morris, *Adv. Mater.*, 2019, **31**, 1902626.
- 125 Q. Chen, G. J. Huang, W. T. Wu, J. W. Wang, J. W. Hu, J. M. Mao, P. K. Chu, H. Z. Bai and G. P. Tang, *Adv. Mater.*, 2020, **32**, 1908185.
- 126 F. G. Guo, J. K. Das, K. S. Kobayashi, Q. M. Qin, T. A. Ficht, R. C. Alaniz, J. X. Song and P. De Figueiredo, *J. Immunother. Cancer*, 2022, **10**, 121.
- 127 R. L. Vincent, C. R. Gurbatri, F. Li, A. Vardoshvili, C. Coker, J. Im, E. R. Ballister, M. Rouanne, T. Savage, K. de Los Santos-Alexis, A. Redenti, L. Brockmann, M. Komaran-chath, N. Arpaia and T. Danino, *Science*, 2023, **382**, 211–218.
- 128 Y. L. Yue, J. Q. Xu, Y. Li, K. M. Cheng, Q. Q. Feng, X. T. Ma, N. N. Ma, T. J. Zhang, X. W. Wang, X. Zhao and G. J. Nie, *Nat. Biomed. Eng.*, 2022, **6**, 898–909.
- 129 Z. X. Chen, T. Y. Yong, Z. H. Wei, X. Q. Zhang, X. Li, J. Q. Qin, J. Y. Li, J. Hu, X. L. Yang and L. Gan, *Adv. Sci.*, 2024, **11**, 2305081.
- 130 B. C. Wei, J. M. Pan, R. T. Yuan, B. F. Shao, Y. Wang, X. Guo and S. B. Zhou, *Nano Lett.*, 2021, **21**, 5905.
- 131 W. F. Chen, Y. N. Zhu, J. H. Chen, X. D. Jing, Y. M. Xiong, L. Zou, J. H. Li, Q. H. Liu, Y. P. Li, Y. Huang and J. H. He, *Adv. Funct. Mater.*, 2023, **33**, 2307001.
- 132 S. Leschner, K. Westphal, N. Dietrich, N. Viegas, J. Jablonska, M. Lyszkiewicz, S. Lienenklaus, W. Falk, N. Gekara, H. Loessner and S. Weiss, *PLoS One*, 2009, **4**, e6692.
- 133 L. N. Liu, X. Liu, W. J. Xin, L. L. Zhou, B. L. Huang, C. Han, Z. T. Cao and Z. C. Hua, *Signal Transduction Targeted Ther.*, 2023, **8**, 134.
- 134 D. M. Pardoll, *Nat. Rev. Cancer*, 2012, **12**, 252–264.
- 135 M. Vétizou, J. M. Pitt, R. Daillère, P. Lepage, N. Waldschmitt, C. Flament, S. Rusakiewicz, B. Routy, M. P. Roberti, C. P. M. Duong, V. Poirier-Colame, A. Roux, S. Becharaf, S. Formenti, E. Golden, S. Cording, G. Eberl, A. Schlitzer, F. Ginhoux, S. Mani, T. Yamazaki, N. Jacquelot, D. P. Enot, M. Béard, J. Nigou, P. Opolon, A. Eggermont, P. L. Woerther, E. Chachaty, N. Chaput, C. Robert, C. Mateus, G. Kroemer, D. Raouf, I. G. Boneca, F. Carbonnel, M. Chamaillard and L. Zitvogel, *Science*, 2015, **350**, 1079–1084.
- 136 V. Gopalakrishnan, C. N. Spencer, L. Nezi, A. Reuben, M. C. Andrews, T. V. Karpinets, P. A. Prieto, D. Vicente, K. Hoffman, S. C. Wei, A. P. Cogdill, L. Zhao, C. W. Hudgens, D. S. Hutchinson, T. Manzo, M. P. de Macedo, T. Cotechini, T. Kumar, W. S. Chen, S. M. Reddy, R. S. Sloane, J. Galloway-Pena, H. Jiang, P. L. Chen, E. J. Shpall, K. Rezvani, A. M. Alousi, R. F. Chemaly, S. Shelburne, L. M. Vence, P. C. Okhuysen, V. B. Jensen, A. G. Swennes, F. McAllister, E. M. R. Sanchez, Y. Zhang, E. Le Chatelier, L. Zitvogel, N. Pons, J. L. Austin-Breneman, L. E. Haydu, E. M. Burton, J. M. Gardner, E. Sirmans, J. Hu, A. J. Lazar, T. Tsujikawa, A. Diab, H. Tawbi, I. C. Glitza, W. J. Hwu, S. P. Patel, S. E. Woodman, R. N. Amaria, M. A. Davies, J. E. Gershenwald, P. Hwu, J. E. Lee, J. Zhang, L. M. Coussens, Z. A. Cooper, P. A. Futreal, C. R. Daniel,

- N. J. Ajami, J. F. Petrosino, M. T. Tetzlaff, P. Sharma, J. P. Allison, R. R. Jenq and J. A. Wargo, *Science*, 2018, **359**, 97–103.
- 137 B. Routy, E. Le Chatelier, L. Derosa, C. P. M. Duong, M. T. Alou, R. Daillère, A. Fluckiger, M. Messaoudene, C. Rauber, M. P. Roberti, M. Fidelle, C. Flament, V. Poirier-Colame, P. Opolon, C. Klein, K. Iribarren, L. Mondragón, N. Jacquelot, B. Qu, G. Ferrere, C. Clémenson, L. Mezquita, J. R. Masip, C. Naltet, S. Brosseau, C. Kaderbhai, C. Richard, H. Rizvi, F. Levenez, N. Galleron, B. Quinquis, N. Pons, B. Ryffel, V. Minard-Colin, P. Gonin, J. C. Soria, E. Deutsch, Y. Loriot, F. Ghiringhelli, G. Zalcman, F. Goldwasser, B. Escudier, M. D. Hellmann, A. Eggermont, D. Raoult, L. Albiges, G. Kroemer and L. Zitvogel, *Science*, 2018, **359**, 91–97.
- 138 M. J. Lin, J. Svensson-Arelund, G. S. Lubitz, A. Marabelle, I. Melero, B. D. Brown and J. D. Brody, *Nat. Cancer*, 2022, **3**, 911–926.
- 139 M. Cronin, R. M. Stanton, K. P. Francis and M. Tangney, *Cancer Gene Ther.*, 2012, **19**, 731–740.
- 140 A. Hyrenius-Wittsten and K. T. Roybal, *Trends Cancer*, 2019, **5**, 583–592.
- 141 W. A. Lim and C. H. June, *Cell*, 2017, **168**, 724–740.
- 142 S. A. Richman, S. Nunez-Cruz, B. Moghimi, L. Z. Li, Z. T. Gershenson, Z. Mourelatos, D. M. Barrett, S. A. Grupp and M. C. Milone, *Cancer Immunol. Res.*, 2018, **6**, 36–46.
- 143 K. R. Parker, D. Migliorini, E. Perkey, K. E. Yost, A. Bhaduri, P. Bagga, M. Haris, N. E. Wilson, F. Liu, K. Gabunia, J. Scholler, T. J. Montine, V. G. Bhoj, R. Reddy, S. Mohan, I. Maillard, A. R. Kriegstein, C. H. June, H. Y. Chang, A. D. Posey and A. T. Satpathy, *Cell*, 2020, **183**, 126–142.
- 144 R. G. Majzner and C. L. Mackall, *Cancer Discovery*, 2018, **8**, 1219–1226.
- 145 D. M. O'Rourke, M. P. Nasrallah, A. Desai, J. J. Melenhorst, K. Mansfield, J. J. D. Morrisette, M. Martinez-Lage, S. Brem, E. Maloney, A. Shen, R. Isaacs, S. Mohan, G. Plesa, S. F. Lacey, J. M. Navenot, Z. H. Zheng, B. L. Levine, H. Okada, C. H. June, J. L. Brogdon and M. V. Maus, *Sci. Transl. Med.*, 2017, **9**, eaaa0984.
- 146 K. M. Cappell and J. N. Kochenderfer, *Nat. Rev. Clin. Oncol.*, 2023, **20**, 359–371.
- 147 A. Jakovija and T. Chtanova, *Front. Immunol.*, 2023, **14**, 1060258.
- 148 Z. Mi, Q. Yao, Y. Qi, J. H. Zheng, J. H. Liu, Z. G. Liu, H. P. Tan, X. Q. Ma, W. H. Zhou and P. F. Rong, *Acta Pharm. Sin. B*, 2023, **13**, 819–833.
- 149 J. Chen, Y. Qiao, G. Chen, C. Chang, H. Dong, B. Tang, X. Cheng, X. Liu and Z. Hua, *Acta Pharm. Sin. B*, 2021, **11**, 3165–3177.
- 150 D. S. Leventhal, A. Sokolowska, N. Li, C. Plescia, S. A. Kolodziej, C. W. Gallant, R. Christmas, J. R. Gao, M. J. James, A. Abin-Fuentes, M. Momin, C. Bergeron, A. Fisher, P. F. Miller, K. A. West and J. M. Lora, *Nat. Commun.*, 2020, **11**, 2739.
- 151 Y. Qiu, M. X. Su, L. Y. Liu, Y. Q. Tang, Y. Pan and J. B. Sun, *Drug Des., Dev. Ther.*, 2021, **15**, 2269–2287.
- 152 V. Nicaise, M. Roux and C. Zipfel, *Plant Physiol.*, 2009, **150**, 1638–1647.
- 153 H. L. Yin, N. Pu, Q. D. Chen, J. C. Zhang, G. C. Zhao, X. F. Xu, D. S. Wang, T. T. Kuang, D. Y. Jin, W. H. Lou and W. C. Wu, *Cell Death Dis.*, 2021, **12**, 1033.
- 154 D. S. Leventhal, A. Sokolowska, N. Li, C. Plescia, S. A. Kolodziej, C. W. Gallant, R. Christmas, J. R. Gao, M. J. James, A. Abin-Fuentes, M. Momin, C. Bergeron, A. Fisher, P. F. Miller, K. A. West and J. M. Lora, *Nat. Commun.*, 2020, **11**, 2739.
- 155 B. Wei, J. Pan, R. Yuan, B. Shao, Y. Wang, X. Guo and S. Zhou, *Nano Lett.*, 2021, **21**, 4231–4240.
- 156 H. Zhang, Y. Wang, L. Zhu, Z. Qi, K. Cao, J. Chang and L. Hou, *J. Controlled Release*, 2023, **360**, 660–671.
- 157 M. Du, T. Wang, R. J. Feng, P. H. Zeng and Z. Y. Chen, *Front. Bioeng. Biotechnol.*, 2023, **11**, 1144963.
- 158 K. Liu, L. Wang, J. Peng, Y. Lyu, Y. Li, D. Duan, W. Zhang, G. Wei, T. Li, Y. Niu and Y. Zhao, *Adv. Mater.*, 2024, **36**, e2310735.
- 159 Y. Zhou, Q. Li, Y. Wu, W. Zhang, L. Ding, C. Ji, P. Li, T. Chen, L. Feng, B. Z. Tang and X. Huang, *Adv. Mater.*, 2024, **36**, e2313953.
- 160 Q. N. Ye, Y. Wang, S. Shen, C. F. Xu and J. Wang, *Adv. Healthcare Mater.*, 2021, **10**, 2002139.
- 161 J. Martinez-Quintanilla, I. Seah, M. Chua and K. Shah, *J. Clin. Invest.*, 2019, **129**, 1407–1418.
- 162 S. Sindhvani, A. M. Syed, J. Ngai, B. R. Kingston, L. Maiorino, J. Rothschild, P. MacMillan, Y. W. Zhang, N. U. Rajesh, T. Hoang, J. L. Y. Wu, S. Wilhelm, A. Zilman, S. Gadde, A. Sulaiman, B. Ouyang, Z. Lin, L. S. Wang, M. Egeblad and W. C. W. Chan, *Nat. Mater.*, 2020, **19**, 566–575.
- 163 R. Ngoune, A. Peters, D. von Elverfeldt, K. Winkler and G. Pütz, *J. Controlled Release*, 2016, **238**, 58–70.
- 164 R. Liu, Z. P. Cao, L. Wang, X. Y. Wang, S. S. Lin, F. Wu, Y. Pang and J. Y. Liu, *Nano Today*, 2022, **45**, 101537.
- 165 Q. J. Chen, T. Sun and C. Jiang, *Nano-Micro Lett.*, 2021, **13**, 1–47.
- 166 J. J. Li, Q. Xia, H. Y. Guo, Z. Z. Fu, Y. Liu, S. S. Lin and J. Y. Liu, *Angew. Chem., Int. Ed.*, 2022, **134**, e202202409.
- 167 N. Sethi and Y. B. Kang, *Nat. Rev. Cancer*, 2011, **11**, 735–748.
- 168 C. Munguti, M. C. Mutebi, M. Ng'ang'a and R. Wasike, *J. Clin. Oncol.*, 2020, **38**, 12508.
- 169 L. Bracci, G. Schiavoni, A. Sistigu and F. Belardelli, *Cell Death Differ.*, 2014, **21**, 15–25.
- 170 L. Chen, W. Q. Hong, W. Y. Ren, T. Xu, Z. Y. Qian and Z. Y. He, *Signal Transduction Targeted Ther.*, 2021, **6**, 225.
- 171 D. S. Leventhal, A. Sokolowska, N. Li, C. Plescia, S. A. Kolodziej, C. W. Gallant, R. Christmas, J. R. Gao, M. J. James, A. Abin-Fuentes, M. Momin, C. Bergeron, A. Fisher, P. F. Miller, K. A. West and J. M. Lora, *Nat. Commun.*, 2020, **11**, 2739.
- 172 R. B. Patel, M. Z. Ye, P. M. Carlson, A. Jaquish, L. Zangl, B. Ma, Y. Y. Wang, I. Arthur, R. S. Xie, R. J. Brown, X. Wang,

- R. Sriramaneni, K. Kim, S. Q. Gong and Z. S. Morris, *Adv. Mater.*, 2019, **31**, 1902626.
- 173 J. W. Jiang, Y. J. Huang, Z. S. Zeng and C. S. Zhao, *ACS Nano*, 2023, **17**, 843–884.
- 174 Z. Y. Liao, W. T. Zhang, H. Q. Zheng, Y. F. Wang, J. C. Yu, H. J. Li and Z. Gu, *J. Controlled Release*, 2022, **344**, 272–288.
- 175 P. Xu, C. Clark, T. Ryder, C. Sparks, J. P. Zhou, M. Wang, R. Russell and C. Scott, *Biotechnol. Prog.*, 2017, **33**, 478–489.
- 176 C. Flowers, B. Chastek, L. Becker, D. Mahmoud and E. Dulac, *Haematologica*, 2014, **99**, 784–785.
- 177 J. X. Fan, M. Y. Peng, H. Wang, H. R. Zheng, Z. L. Liu, C. X. Li, X. N. Wang, X. H. Liu, S. X. Cheng and X. Z. Zhang, *Adv. Mater.*, 2019, **31**, 1808278.
- 178 T. Danino, A. Prindle, G. A. Kwong, M. Skalak, H. Li, K. Allen, J. Hasty and S. N. Bhatia, *Sci. Transl. Med.*, 2015, **7**, 289ra284.
- 179 V. Staedtke, R. Y. Bai, K. Kim, M. Darvas, M. L. Davila, G. J. Riggins, P. B. Rothman, N. Papadopoulos, K. W. Kinzler, B. Vogelstein and S. B. Zhou, *Nature*, 2018, **564**, 273–277.
- 180 W. J. Luo, C. G. Li, Y. Q. Zhang, M. Y. Du, H. M. Kou, C. Lu, H. Mei and Y. Hu, *BMC Cancer*, 2022, **22**, 98.
- 181 X. H. Huang, J. M. Pan, F. N. Xu, B. F. Shao, Y. Wang, X. Guo and S. B. Zhou, *Adv. Sci.*, 2021, **8**, 2003572.
- 182 M. X. Hao, S. Y. Hou, W. S. Li, K. M. Li, L. J. Xue, Q. F. Hu, L. L. Zhu, Y. Chen, H. B. Sun, C. Y. Ju and C. Zhang, *Sci. Transl. Med.*, 2020, **12**, eaaz6667.
- 183 L. Guo, H. Chen, J. Ding, P. Rong, M. Sun and W. Zhou, *Exploration*, 2023, **3**, 20230017.
- 184 S. Lin, F. Wu, Y. Zhang, H. Chen, H. Guo, Y. Chen and J. Liu, *Chem. Soc. Rev.*, 2023, **52**, 6617–6643.
- 185 Z. P. Cao and J. Y. Liu, *Acc. Mater. Res.*, 2024, **23**, 1162.
- 186 D. Hu, H. Xu, W. Zhang, X. Xu, B. Xiao, X. Shi, Z. Zhou, N. K. H. Slater, Y. Shen and J. Tang, *Biomaterials*, 2021, **277**, 121130.
- 187 H. Pan, M. Zheng, A. Ma, L. Liu and L. Cai, *Adv. Mater.*, 2021, **33**, e2100241.
- 188 D. Lin, X. Feng, B. Mai, X. Li, F. Wang, J. Liu, X. Liu, K. Zhang and X. Wang, *Biomaterials*, 2021, **277**, 121124.
- 189 X. Guan, J. Chen, Y. Hu, L. Lin, P. Sun, H. Tian and X. Chen, *Biomaterials*, 2018, **171**, 198–206.